

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pakola *et al.*

Serial No.: 10/729,475

Filing Date: December 5, 2003

Docket No.: 113476.122US1

Title: PHARMACOLOGICAL VITREOLYSIS

Art Unit: 1651

Examiner: Taeyoon Kim

Conf. No.: 3082


Cust. No.: 23483

CERTIFICATION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail on the date indicated below and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2/11/08

Date of Deposit

  
Rochelle Capobianco

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF DR. STEVE PAKOLA UNDER 37 C.F.R. § 1.132

Dear Sir:

In connection with the above-referenced patent application, I, Steve Pakola, declare as follows:

1. I received my M.D. degree from University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Prior to my current employment with ThromboGenics, I was Associate Director, Cardiovascular Clinical Research, at Boehringer-Ingelheim Pharmaceuticals. Prior to Boehringer-Ingelheim, I also served in senior-level clinical development positions at Quintiles Cardiovascular Therapeutics and Organon, Inc. I am a licensed physician with extensive clinical trial experience, including over 11 years in pharma/biotech clinical development. My *curriculum vitae* is provided as Attachment 1 following page 13 of this Declaration.

2. Currently, I have the position of Chief Medical Officer at ThromboGenics.
3. I am a co-inventor of the above-referenced patent application. I have read and am familiar with the above-referenced patent application. I am also familiar with the Office Action which issued in the above-referenced application on October 16, 2007.
4. As I understand the Office Action dated October 16, 2007, the Examiner's primary basis for the obviousness rejections is that the skilled artisan would have been motivated to replace plasmin in the method of Trese *et al.* with the microplasmin of Collen *et al.* and Wu *et al.* "because both plasmin and microplasmin share the same enzymatic activity as well known in the art, thus these are considered art-recognized equivalents" (see, Office Action, page 4).
5. We compared the properties of plasmin and microplasmin using several parameters. Specifically, we (i) compared the kinetics of inhibition of  $\alpha$ 2-antiplasmin by plasmin and microplasmin; (ii) compared the ability of plasmin and microplasmin to lyse purified fibrin clots; (iii) compared plasmin and microplasmin with respect to hydrolysis of several substrates (fibrin, fibrinogen, collagen type IV, gelatin, laminin, and fibronectin); and (iv) compared plasmin and microplasmin with respect to the rate of hydrolysis of several substrates. In each of these experiments, the data shows that microplasmin and plasmin have significantly different proteolytic activity profiles. The experimental data from these studies is provided below.
6. Microplasmin and plasmin used in the experiments described in this Declaration were prepared as follows. Human microplasminogen, which lacks the five kringle domains of plasminogen, was recombinantly expressed with high yield in *Pichia pastoris*. It was purified, converted to microplasmin and equilibrated with 5 mM citrate, pH 3.1, yielding a stable preparation as was done and described in, Examples 1 and 2 of our patent application.

Natural plasmin purified from human plasma was purchased from Haematologic Technologies Inc. (Essex Junction, VT, USA) or was prepared in-house as 20  $\mu$ M solution (as

determined by active site titration using the NPGB titration (see below) in 0.05 M phosphate buffer, pH 7.4, containing 20% (v/v) glycerol as previously described (Lijnen *et al.*, 1987, *Eur. J. Biochem.* 169:359-364).

7. Comparison of Kinetics of Inhibition by  $\alpha_2$ -antiplasmin by Plasmin and Microplasmin:

The natural plasmin inhibitor, human  $\alpha_2$ -antiplasmin, was prepared in-house as a 25  $\mu$ M solution (as determined by titration with natural human plasmin) in 0.05 M Tris-HCl buffer, pH 7.4 containing 0.038 M NaCl and 0.01% Tween 80 as previously described (Wiman 1980, *Biochem. J.*, 191:229-232). Three different batches of microplasmin were used in these studies: batch A is a pilot-scale production of microplasmin, whereas batches B and C are two different lab-scale productions. The kinetics of the inhibition by  $\alpha_2$ -antiplasmin of microplasmin and plasmin was determined by measuring the second-order rate constant  $k_1$ . The second-order rate constant  $k_1$  yielded:

$$k_1 = 1.0 \pm 0.08 \times 10^7 \text{ M}^{-1} \cdot \text{s}^{-1} \text{ for natural plasmin (mean} \pm \text{ SEM, } n = 4\text{)}$$

$$k_1 = 2.5 \pm 0.28 \times 10^5 \text{ M}^{-1} \cdot \text{s}^{-1} \text{ for microplasmin of a batch A (mean} \pm \text{ SEM, } n = 3\text{)}$$

$$k_1 = 3.0 \pm 0.19 \times 10^5 \text{ M}^{-1} \cdot \text{s}^{-1} \text{ for microplasmin of a batch B (mean} \pm \text{ SEM, } n = 3\text{)}$$

$$k_1 = 2.7 \pm 0.12 \times 10^5 \text{ M}^{-1} \cdot \text{s}^{-1} \text{ for microplasmin of a batch C (mean} \pm \text{ SEM, } n = 3\text{)}$$

Natural plasmin is quantitatively complexed by  $\alpha_2$ -antiplasmin after incubation for 3 minutes with equimolar concentration of  $\alpha_2$ -antiplasmin, whereas even after incubation for 30 minutes with 3-fold molar excess, microplasmin was not quantitatively complexed.

Thus, microplasmin and plasmin significantly differ in their ability to be inhibited by  $\alpha_2$ -antiplasmin.

8. Comparison of Plasmin with Microplasmin in Lysing Purified Fibrin Clots:

$^{125}\text{I}$ -labeled cross-linked clots of purified human fibrin were prepared by addition of  $\text{CaCl}_2$  (final concentration 35 mM) and thrombin (final concentration 1.0 NIH U/mL) to purified

plasminogen-depleted human fibrinogen (final concentration 4 mg/mL, containing approximately 50,000 cpm of  $^{125}\text{I}$ -labeled human fibrinogen in 0.9% NaCl). After incubation at 37°C for 60 minutes in silicon tubing (internal diameter 4 mm), pieces of 0.5 cm length were cut off. The fibrin clots were extensively washed in 0.05 M Tris-HCl buffer, pH 7.4, containing 0.038 M NaCl and 0.01% Tween 80 and incubated in 500  $\mu\text{L}$  fibrinogen (4 mg/mL in 0.9% NaCl) at 37°C with addition of the plasmin moieties (0 - 100 nM). Lysis of the clots after incubation of 1, 2, or 3 hours was quantitated by the release of radioactivity from the clot into the surrounding liquid as measured by a gamma scintillation counter and expressed as percent of the total radioactivity incorporated in the clot.

Spontaneous clot lysis (without addition of enzyme) was  $\leq$ 8.8% in all experiments. The concentration of plasmin moiety required for 50% clot lysis in 3 hours, is estimated at  $\approx$ 100 nM for the microplasmin preparations in contrast to only  $\approx$ 20 nM for natural plasmin.

Thus, as compared to intact human plasmin, the fibrinolytic potency of the microplasmin preparations towards purified fibrin clots appeared to be 4- to 5-fold lower.

9. Hydrolysis of Fibrinogen, Collagen Type IV, Gelatin, Laminin, and Fibronectin:

Collagen type IV from human placenta, Oregon Green 488 conjugate, was purchased from Molecular Probes (Eugene, OR, USA). Gelatin from pig skin, Oregon Green 488 conjugate, was purchased from Molecular Probes (Eugene, OR, USA). Fibrinogen from human plasma, Oregon Green 488 conjugate, was purchased from Molecular Probes (Eugene, OR, USA). Fibronectin from human foreskin fibroblasts, was purchased from Sigma-Aldrich Co (St Louis, MO, USA). Laminin from human placenta, was purchased from Sigma-Aldrich Co (St Louis, MO, USA). Oregon Green 488 Protein labeling kit, was purchased from Molecular Probes (Eugene, OR, USA). Substrates that were not commercially available as fluorescently labeled proteins, *i.e.*, laminin and fibronectin, were labeled with the Oregon Green 488 Labeling kit according the manual provided by the manufacturer.

Substrate compound lysis tests were performed in 96-well microplates. The walls of these wells were coated with 5  $\mu\text{g}$  of the fluorescently labeled substrate (overnight in an oven at

30°C). Plates were then washed four times, each time for 15 minutes with 150 µL Tris-buffer (50 mM Tris, 14 mM NaCl, pH 7.4) at 37 °C, on a rotary shaker (350 rpm). 150 µL of microplasmin or natural plasmin solutions diluted in Tris-buffer (50 mM Tris, 14 mM NaCl, 0.01 % Tween (w/v), pH 7.4) in the range of 0.01 to 3000 nM were applied in the wells. Plates were then incubated at 37°C on a rotary shaker (550 rpm). 10 µL of the reaction samples were taken at different time points (0h, 0.25h, 0.5h, 1h, 2h, 3h) and diluted in 190 µL Tris-buffer (50 mM Tris, 14 mM NaCl 14, 0.01 % Tween (w/v), pH 7.4) and the fluorescence of the diluted sample was measured (Ex 496 nm, Em 524 nm, Cut off 515 nm).

For determination of blank values or 100% lysis values, wells were filled with 150 µL Tris-buffer (50 mM Tris, 14 mM NaCl, 0.01% Tween (w/v), pH 7.4) or 3M NaOH, respectively.

Based on the measured fluorescence the following calculations were performed:

- 1) Determination of the concentration of microplasmin or natural plasmin necessary to induce 50% breakdown of fibrinogen, fibronectin, laminin, collagen and gelatin, respectively, at the different time points studied.
- 2) Determination of the rate of hydrolysis represented as percent lysis per hour for microplasmin and plasmin for fibrinogen, fibronectin, laminin, collagen and gelatin, respectively.

The amount of active enzyme present in the samples of the recombinant human microplasmin and natural plasmin used in this study was determined with an active-site titration with NPGB (para-nitrophenyl para-guanidinobenzoate; Fiedler *et al.* (1972), *FEBS Lett.* 24:41-44). For recombinant human microplasmin, the concentration after reconstitution was found to be 4.16 mg/ml, corresponding with 152.8 µM. The natural plasmin used showed to be at a concentration of 12.25 mg of active protein/ml, corresponding with 147.6 µM.

The hydrolysis, expressed as enzyme-concentration (in nM) required to hydrolyze 50% substrate, of fibrinogen, collagen type IV, gelatin, laminin, and fibronectin at 0.25, 0.5, 1, 2, and 3 hours after addition of the enzyme is summarized in Table 1.

**Table 1.** IC50 for microplasmin and natural plasmin for the different substrates at different time points.

Substrate	Microplasmin IC 50 (nM)	Natural Plasmin IC 50 (nM)	Ratio Microplasmin / natural plasmin
<b>Fibrinogen</b>			
0.25h	11	6	1.8
0.5h	4	2.5	1.6
1h	2.1	1.2	1.8
2h	1.2	0.5	2.4
3h	0.7	0.3	2.3
<b>Collagen type IV</b>			
0.25h	290	447	0.6
0.5h	130	143	0.9
1h	65	73	0.9
2h	21	27	0.8
3h	13	17	0.8
<b>Laminin</b>			
0.25h	179	61	2.9
0.5h	117	55	2.1
1h	19	27	0.7
2h	24	22	1.1
3h	18	21	0.9
<b>Gelatin</b>			
0.25h	59	10	5.9
0.5h	26	9	2.9
1h	17	5	3.4
2h	12	4	3.0
3h	14	4	3.5
<b>Fibronectin</b>			
0.25h	34	4.1	8.3
0.5h	11	1.9	5.8
1h	8	1.7	4.7
2h	4	1.2	3.3
3h	2	1.1	1.8

As can be seen from Table 1, at all time points measured more microplasmin than natural plasmin is required to hydrolyze the same amount of fibrinogen, gelatin, or fibronectin. Thus, microplasmin is less efficient in hydrolyzing these substrates as compared to natural plasmin. In the case of the substrate collagen type IV, microplasmin is at all time points slightly more potent than natural plasmin. In the case of substrate laminin, microplasmin is less potent than natural plasmin at the initial time points but nearly equally potent as natural plasmin at the later time points. Moreover, the change in activity over time is much more significant in microplasmin than in plasmin for the substrate laminin. For example, compare the IC50 of 179 nm at 0.25 hours and 19 nm at 1 hour for microplasmin to an IC50 of 61 nm at 0.25 hours to 27 nm at 1 hour for plasmin.

In nearly all of the above instances, the highest concentrations (1000 nM or 3000 nM) of either microplasmin or natural plasmin were able to digest a similar percentage of substrate at the same time point. However, a remarkable difference was noted in the case of the substrate fibronectin for which, at the highest enzyme concentrations, the level of hydrolysis by natural plasmin at all time points was about 20% lower than the level of hydrolysis by microplasmin (see, Figure 1 for microplasmin ("μplasmin"); and Figure 2 for natural plasmin ("plasmin"); Key to Figures: open circles: 0.25 h incubation; open squares: 0.5 h incubation; open triangles: 1 h incubation; open diamonds: 2 h incubation; closed circles: 3 h incubation). In fact, in no case was 100% fibronectin-hydrolysis obtained with natural plasmin, a level that could be obtained with microplasmin.

Figure 1  
fibronectin -  $\mu$ plasmin





Figure 2  
fibronectin / plasmin



10. Rate of Hydrolysis of Collagen Type IV, Fibrinogen, Gelatin, Laminin, and Fibronectin:

The rate of proteolytic degradation of fibrinogen, collagen type IV, gelatin, laminin, and fibronectin by microplasmin and natural plasmin were determined and expressed as percent substrate hydrolysis per hour. It was first determined that an enzyme concentration of 1 nM was needed to obtain a linear rate of hydrolysis of the substrates fibrinogen, gelatin and fibronectin, while for collagen type IV and laminin an enzyme concentration of 30 nM was needed.

Linear regression analysis was applied to the results obtained, and the rates of proteolysis of the different substrates by microplasmin and natural plasmin were derived from the slopes of the respective plots. The results of these studies are summarized in Table 2.

**Table 2.** % lysis per hour for microplasmin and plasmin on the different substrates

% Lysis/h	Microplasmin	Natural Plasmin	Ratio Microplasmin / Natural Plasmin
Fibrinogen (1 nM enzyme)	11.8	20.5	0.58
Gelatin (1 nM enzyme)	8.6	8.7	0.99
Fibronectin (1 nM enzyme)	11.4	20.0	0.57
Collagen type IV (30 nM enzyme)	33.0	26.0	1.27
Laminin (30 nM enzyme)	31.1	18.2	1.71

Natural plasmin degraded the compounds fibrinogen and fibronectin at a higher rate than microplasmin, while for collagen type IV and laminin microplasmin was more effective. Gelatin was degraded at an equal rate by both microplasmin and natural plasmin. This shows a further difference in enzymatic activities for microplasmin versus plasmin.

11. Hydrolysis of Small-Size Artificial Chromogenic Substrates:

Two artificial chromogenic substrates were used in this study, namely S-2403 and S-2444. Both these substrates were obtained from Chromogenix, Milano, Italy. S-2403 (L-Pyroglutamyl-L-phenylalanyl-L-lysine-p-nitroaniline.hydrochloride) is a chromogenic substrate for plasmin at 3 mM in H<sub>2</sub>O. S-2444 (L-Pyroglutamyl-glycyl-L-arginine-p-nitroaniline.hydrochloride) reacts with trypsin and 15-fold less with urokinase at 10 mM in H<sub>2</sub>O, but does not react with plasmin.

The kinetic parameters for hydrolysis of S-2403 (0.05 - 1.0 mM) or S-2444 (0.5 - 4.0 mM) by the different plasmin moieties (final concentration 5 nM for S-2403 and 20 nM for S-2444) were determined by linear regression analysis of Lineweaver-Burk plots. Measurements were performed in 0.05 M Tris-HCl buffer, pH 7.4, containing 0.038 M NaCl and 0.01% Tween 80 at 37°C. Tables 3 and 4 summarize the results of the analysis for S-2403 and S-2444, respectively.

**Table 3.** Catalytic efficiency of natural plasmin and microplasmin for S-2403.

Enzyme	K <sub>m</sub> (mM)	k <sub>cat</sub> (s-1)	k <sub>cat</sub> /K <sub>m</sub> (mM <sup>-1</sup> .s <sup>-1</sup> )	r
natural plasmin	0.112	84.61	755.44	0.9996
microplasmin batch A	0.113	78.59	697.34	0.9989
microplasmin batch B	0.098	78.73	805.01	0.9989
microplasmin batch C	0.081	66.74	819.50	0.9977

**Table 4.** Catalytic efficiency of natural plasmin and microplasmin for S-2444.

Enzyme	Km (mM)	kcat (s-1)	kcat/Km (mM-1.S-1)	r
natural plasmin	6.380	57.00	8.93	0.9995
microplasmin batch A	4.989	38.60	7.74	0.9995
microplasmin batch B	5.060	43.63	8.62	0.9996
microplasmin batch C	5.574	43.03	7.72	0.9999

No significant differences between the plasmin and microplasmin moieties were observed with respect to the catalytic efficiencies towards the synthetic chromogenic substrates S-2403 or S-2444. While this data shows similar activities for 2 synthetic substrates, the data presented above shows differing activities for natural substrates.

12. These data, in total, teach different activities for the natural substrates of plasmin and microplasmin. This would suggest that the *in vivo* activities of the two enzymes would be different. Taken together, these data clearly indicate that microplasmin and plasmin have significantly different molecular properties. They do not share the same enzymatic activity and would not be recognized in the art as being equivalent.

13. One potential explanation for the difference in activities between the microplasmin and plasmin is the absence of the kringle domains in microplasmin. The kringle of plasmin are known to be the basis for interaction with several proteins. Thus, a person of ordinary skill in the art would not recognize the equivalence of plasmin and microplasmin, and would not expect their enzymatic activities to be the same. In fact, in my opinion, a person of skill in the art would not expect plasmin and microplasmin to have the same or similar activity because of the lack of kringle domains in microplasmin.

14. Moreover, the fact that microplasmin was shown by Collen (WO 2002/50290) to be useful for the treatment of local cerebral ischemic infarctions does not teach or suggest to a person of ordinary skill in the art that microplasmin would also be useful for liquefying the vitreous, inducing posterior vitreous detachment, or for treating a vitreoretinal disease or disorder. These indications are entirely different.

15. Likewise, the *in vitro* teachings of Wu (US 4,774,087) in the Examples section of this patent do not teach or suggest to a person of ordinary skill in the art that microplasmin would also be useful for liquefying the vitreous, inducing posterior vitreous detachment, or for treating a vitreoretinal disease or disorder.

16. A person of ordinary skill in the art would not have considered substituting plasmin with microplasmin in the method of Trese (US 5,304,118) because of safety concerns relating to the fact that microplasmin is expected to diffuse better through the vitreous than plasmin. Indeed, one of skill in the art would expect microplasmin not only to diffuse better through the vitreous, but also to diffuse more easily and deeper into eye tissues such as the inner limiting membrane and/or retina. Such an effect would cause severe tissue damage, an effect certainly not desired in the eye as it would severely compromise vision. Thus, one of ordinary skill would not have considered substituting plasmin with microplasmin in the method of Trese for introduction into the eye.

17. Nor would the use of microplasmin for stroke teach or suggest that microplasmin would be safe when administered to the eye. Because of the different routes of administration, different organ systems involved, and different mechanisms of action involved, one of ordinary skill in the art would not assume that microplasmin could safely be administered to the eye.

18. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: Feb 04, 2008



Steve Pakola, M.D.

**ATTACHMENT 1**

Attached is the *curriculum vitae* of Dr. Steve Pakola.

**Stephen J. Pakola, M.D.**

11 Meadow Way

Irvington, NY 10533

Home Phone: 1-914-674-1947

email: steve.pakola@thrombogenics.com

**Professional Summary:** A licensed physician with over 13 years of clinical trial experience, including over 11 years of full-time Pharma/Biotech experience in roles of increasing responsibility (currently Chief Medical Officer of ThromboGenics and member of the Board of Directors of ThromboGenics Ltd.).

**Education**

M.D., University of Pennsylvania, Philadelphia, PA, 1994

\*Alpha Omega Alpha (national medical honor society) elected 1993

\*Charles A. Oliver Prize (awarded annually to a graduating medical student at the University of Pennsylvania), 1994

B.A., University of Pennsylvania, Philadelphia, PA, 1990

\*Summa cum laude (GPA-3.9) with honors in biology

\*Phi Beta Kappa, elected 1989

**Professional Experience**

5/00-Present	Chief Medical Officer (Promoted from Senior VP in 6/06, promoted from VP on 7/02) Member of the Board of Directors, ThromboGenics Ltd. *Responsible for the company's worldwide clinical development programs (vitreoretinal disease, AMI, ischemic stroke, DVT prophylaxis, oncology, and other programs to enter clinical development in future) *Program Leader for microplasmin-vitreoretinal program.
11/98-5/00	Associate Director, Cardiovascular Clinical Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT  *U.S. clinical leader for oral direct thrombin inhibitor (BIBR) program *Global Medical Leader of clinical development program for BIBB 1464, a lipid-lowering agent. *Named to Clinical Expert Committee for risk factor intervention (internal expert group to review discovery/development plans for Boehringer Ingelheim worldwide)
6/97-11/98	Associate Director, Organon, Inc. CNS Clinical, West Orange, NJ

	<ul style="list-style-type: none"> <li>*Clinical Development Team Leader for gepirone (prior to departure, in charge of the preparation of the clinical section of NDA and clinical development plan for US)</li> <li>*Unit head award recipient, 1<sup>st</sup> quarter, 1998 (awarded by executive director of clinical department to employees who have made significant contributions to the department)</li> <li>*Study manager for 2 multicenter clinical trials (phase III ten-site trial and a phase IV, five-site trial)</li> <li>*Responsible for safety related issues for U.S. phase II-IV trials on all CNS projects.</li> </ul>
1996-1997	<p>Senior Medical Scientist, Cardiovascular Division, Quintiles, Inc., Research Triangle Park, N.C.</p> <ul style="list-style-type: none"> <li>*Project Medical Officer on all clinical trials in the U.S. Cardiovascular division, including phase I through global phase III trials (including GUARDIAN trial)</li> <li>*Presented at FDA Advisory Committee meeting, as well as numerous investigator meetings</li> </ul>
1995-1996	<p>Research Scientist and Ophthalmology Resident, University of Pennsylvania, F.M. Kirby Center for Gene Therapy</p> <ul style="list-style-type: none"> <li>*Planned and performed experiments in biotechnology arena, including virus vector gene transfer techniques</li> <li>*Authored multiple publications (including one book chapter), and presented work at 4 national meetings</li> <li>*Served as a reviewer for a medical journal</li> </ul>
1994-1995	<p>Medical Intern Physician, Presbyterian Medical Center (Affiliate of University of Pennsylvania Medical Center), Philadelphia, PA</p>

#### **Other**

- \*99% on GMAT (Graduate Management Admission Test)
- \*Unrestricted license to practice medicine (License: NC 9700351)
- \*Married with 3 children

## Original Papers

Pakola SJ and Grunwald JE: Effects of oxygen and carbon dioxide on human retinal circulation. *Investigative Ophthalmology & Visual Science* 34(10): 2866-70, 1993.

MacGregor RR, Pakola SJ, Graziani AL, et al: CMV infection in clinically stable HIV-infected individuals with CD4-positive lymphocyte counts below 100/ul of blood: prevalence and relationship to risk of subsequent CMV retinitis. *Journal of AIDS* 10:324-30, 1995.

Pakola SJ, Dinges DF, Pack AI: Review of regulations and guidelines for commercial and non-commercial drivers with sleep apnea and narcolepsy. *Sleep* 18 (9): 787-96, 1995.

Pakola SJ, Nichols CW: CD8+ cells and cytomegalovirus retinitis in AIDS patients (correspondence). *Am. J. Ophthalmol.* 121(4): 455, 1996

Bennett J, Pakola S, Zenk Y, Maguire A: Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. *Human Gene Therapy* 7(14): 1763-9, 1996

Balcer L, Galetta S, Bagley L, Pakola S: Localization of traumatic oculomotor nerve palsy to the midbrain exit sight by M.R.I. *Am. J. Ophthalmol.* 122(3): 437-9, 1996.

Lapchak PA, Araujo DM, Pakola SJ, Song D, Wei J, Zivin JA.: Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. *Stroke*. 33: 2279-2284, 2002.

Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf F; CAPTORS II Investigators. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). *Am Heart J.* 146(3):484-8, 2003.

Rasmussen RS, Overgaard K, Pakola S, Boysen G. Microplasmin may improve recovery in a rat embolic stroke model. *Neurol Res.* 2007 Jun 19; [Epub ahead of print].

Sakuma T, Tanaka M, Mizota A, Junji Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. *Invest Ophthalmol Vis Sci.* 2005 Sep;46(9):3295-9.

## Chapters

Pack AI, Pakola SJ, Findley LJ: Regulations for driving for patients with sleep disorders. *Forensic aspects of sleep*. Edited by Shapiro C, McCall-Smith. A. John Wiley & Sons Limited, 1996.

**APPENDIX B**

Attached is a copy of International Appl. No. PCT/US2005/013562 (International Publ. No. WO 2005/105990).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number  
WO 2005/105990 A2

(51) International Patent Classification<sup>7</sup>: C12N 9/68 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US2005/013562 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 21 April 2005 (21.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/564,472 22 April 2004 (22.04.2004) US

(71) Applicant (for all designated States except US): TALECRIS BIOTHERAPEUTICS, INC. [US/US]; 4101 Research Commons, 79 T.W. Alexander Drive, RTP, NC 27709 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HUNT, Jennifer, Audrey [US/US]; 8709 O'Neal Road, Raleigh, NC 27613 (US). NOVOKHATNY, Valery [UA/US]; 4617 Wee Burn Trail, Raleigh, NC 27612 (US).

(74) Agent: MASSEY, Carl, B., Jr; Womble Carlyle Sandridge & Rice, PLLC, One Atlantic Center; Ste. 3500, 1201 West Peachtree Street, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:


- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANTLY MODIFIED PLASMIN

WO 2005/105990 A2

## Delta-plasminogen



(57) Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

## RECOMBINANTLY MODIFIED PLASMIN

## Background of the Invention

5 Human plasminogen is a single-chain protein containing 791 amino acid residues. Activation of plasminogen to plasmin results from a single cleavage of the Arg561-Val562 peptide bond in the zymogen. The resulting plasmin molecule is a two-chain, disulfide-linked serine protease with trypsin-like specificity (cleaves after Lys and Arg).

10 The amino-terminal heavy chain of plasmin (residues 1-561, ~60 kDa) is composed of five kringle domains, each containing approximately 80 amino acid residues. The kringle domains are responsible for the regulatory properties of plasminogen, such as interaction with activation inhibitors, *e.g.*, Cl<sup>-1</sup> ions; with activation stimulators, *e.g.*,  $\epsilon$ -aminocaproic acid; with mammalian and bacterial cells; 15 and with other proteins, such as plasmin physiological substrate fibrin and plasmin inhibitor  $\alpha$ 2-antiplasmin. Of all five kringle, kringle 1 is one of the most multi-functional: its lysine-binding activity has been shown to be responsible for plasmin interaction with  $\alpha$ 2-antiplasmin and fibrin. See Wiman, B., *et al.*, *Biochim. Biophys. Acta* 579:142-154 (1979); and Lucas, M.A., *et al.*, *J. Biol. Chem.* 258:4249-4256 20 (1983).

The C-terminal light chain of plasmin (residues 562-791, ~25kDa) is a typical serine protease, homologous to trypsin and containing the classic serine protease catalytic triad: His603, Asp646 and Ser741. Plasminogen contains 24 disulfide bridges and 2 glycosylation sites, on Asn289 and Thr346.

25 The limited proteolysis of plasminogen by elastase has been shown to result in three fragments (Sottrup-Jensen, L., *et al.*, *Prog. Chem. Fibrinol. Thrombol.*, 3:191-209 (1978)). First fragment, K1-3, includes the first three kringle and can be isolated in two versions, Tyr79-Val338 and Tyr79-Val354. The second fragment, K4, corresponds to the fourth kringle and includes residues Val355-Ala440. The last, C- 30 terminal fragment (the so-called mini-plasminogen) includes residues Val443-Asn791 and consists of the fifth kringle and the serine protease domain. Mini-plasminogen can be activated in the same way as plasminogen, forming mini-plasmin.

Because of the complex structure of the full-length plasminogen molecule, bacterial expression systems have not proven useful for recombinant plasminogen production. Plasminogen is produced in the form of insoluble inclusion bodies and is not re-foldable from that state. Further, the expression of plasminogen in mammalian 5 cells is complicated by intracellular activation of plasminogen into plasmin and the resulting cytotoxicity. Production of fully active plasminogen using insect cells is possible, however, this system is not suitable for large-scale production due to low yield.

Accordingly, a modified recombinant protein, possessing the desirable characteristics of plasmin/plasminogen while lacking certain negative characteristics and 10 being capable of production in bacterial cells in substantial quantities, is desirable.

### Summary of the Invention

The present invention provides a polynucleotide comprising a nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain 15 homologous to a kringle domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine. The N-terminal kringle domain can be homologous to kringle 1 or kringle 4 of native human plasminogen.

20 In some embodiments, the encoded polypeptide is at least 90%, 95%, or 98% identical to the sequence shown in SEQ ID NO:2. Further, the encoded polypeptide can be the sequence shown in SEQ ID NO:2.

The nucleotide sequence of the polynucleotide can be the sequence shown in SEQ ID NO:1 or degenerate variations thereof. The nucleotide sequence can 25 encode a polypeptide having an N-terminal kringle domain homologous to the kringle 1 or kringle 4 domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen. The nucleotide sequence can also encode a polypeptide having a single N-terminal kringle domain at least 90% identical to the kringle 1 or kringle 4 domain of 30 native human plasminogen; and a C-terminal domain at least 90% identical to the activation site and serine protease domain of human plasminogen. The encoded polypeptides can bind immobilized lysine.

In another aspect, the invention provides polypeptides having an N-terminal kringle domain homologous to a kringle domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen.

5 In some embodiments, the polypeptides can have an N-terminal kringle domain homologous to kringle 1 or kringle 4 of native human plasminogen.

In some embodiments, the polypeptides can exhibit a fibrinolytic activity that is inhibited by  $\alpha_2$ -antiplasmin at a rate that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by  $\alpha_2$ -antiplasmin. The rate of 10 inhibition by  $\alpha_2$ -antiplasmin can also be at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin.

In some embodiments, the polypeptides can bind immobilized lysine. The immobilized lysine can be lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-BIOGEL (BioRad, Hercules, CA), lysine-15 HYPERD (Pall Life Sciences, East Hills, NY, a lysine-hydrogel), lysine-SEPHAROSE (SEPHAROSE is cross-linked agarose). The immobilized lysine can be lysine-SEPHAROSE.

In some embodiments, the polypeptides can exhibit a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.

20 In some embodiments, the polypeptides can exhibit higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.

In some embodiments, the polypeptides can have a single kringle domain located 25 N-terminal to a plasminogen activation site and plasminogen serine protease domain, wherein the kringle domain has at least one residue greater amino acid sequence identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen. For these embodiments, it will be understood that conservative substitutions of the kringle regions of the polypeptides of the invention, relative to the native sequences of kringle 1 and 4 of human plasminogen, would not be considered as 30 differing from the native sequences for purposes of the identity comparison with kringle 5.

In some embodiments, the polypeptides can have the amino acid sequence as shown in SEQ ID NO:2, and conservative substitutions thereof. The polypeptides can

have a residue at a relative position analogous to that of position 76 of the amino acid sequence shown in SEQ ID NO: 2 that is arginine.

In another aspect, the invention includes vectors comprising the polynucleotides of the invention, and cultured host cells comprising the vectors.

5

#### Brief Description of the Drawings

Figure 1 is a schematic representation of native plasmin after activation by proteolytic cleavage. K1-K5 are kringle regions 1-5; and SP is the serine protease domain. “ $\alpha$ 2-AP” is the  $\alpha$ 2-antiplasmin binding site on kringle 1.

10 Figure 2 is a schematic representation of a plasminogen deletion mutant of the invention using the same nomenclature as in Figure 1, and showing the deletion of K2-5.

15 Figure 3 shows the amino acid sequence of human plasminogen, showing the 19-residue leader sequence numbered as -19 to -1, and the plasminogen sequence shown as residues 1- 791 (see SEQ ID NO:3 (cDNA sequence for human plasminogen; and SEQ ID NO:4, the encoded amino acid sequence, as shown in Figure 3). A number of features are shown, including the following: the delta-plasminogen sequence (shaded); kringle domains 1-5 (double underscore); glycosylations sites Asn289 and Thr346 (in bold); the plasminogen activation Arg-Val 20 activation site (in bold); and lysine-binding sites in kringle 1 (in underscore and with specific position numbering).

Figure 4 shows polypeptide sequence comparisons between the five kringle domains (1-5) of native human plasmin(ogen). Amino acid residues that are identical to those of the same relative position in kringle 1 are shown in underscore.

25 Figure 5 shows a 8-25% gradient SDS-PAGE of a non-reduced (Lane 1) and reduced (Lane 2) delta-plasminogen preparation. Activation of delta-plasminogen into delta-plasmin with streptokinase (Lane 3), tissue Plasminogen Activator (tPA) (Lane 4), and urokinase (Lane 5) results in the formation of the two-chain molecule consisting of kringle 1 (K1) and the serine protease domain (SP) connected by two 30 disulfide bridges.

Figure 6 is a graphic representation of activation of delta-plasminogen by urokinase. Urokinase (5.8 nM) was added to a solution of 5  $\mu$ M delta-plasminogen in

PBS containing 1.0 mM S-2251 at 37°C. Increases in absorbance were monitored at 405 nm.

Figure 7 is a chromatogram showing binding of delta-plasminogen to lysine-SEPHAROSE 4B: 0.5 mg of purified Delta-plasminogen was applied on the lysine-5 SEPHAROSE 4B column (1x3 cm) equilibrated with Tris-buffered saline, pH 7.4. Bound protein was eluted from the column by a 0-20 mM gradient of  $\epsilon$ -aminocaproic acid ( $\epsilon$ -ACA) as a single peak. The absorbance at 280 nm and the concentration of  $\epsilon$ -ACA, as a function of the effluent volume are presented on the graph.

Figure 8 shows binding of delta-plasminogen to fibrin. Varying concentrations 10 of delta-plasminogen were incubated with fibrin clots in a microtiter plate for 1 hour at 37°C. After incubation the clots were washed extensively with PBS and a 0.1mg/ml solution of tPA was added to each well. After a 2-hour incubation at 37 °C the liquid was removed and remaining solid clots were reconstituted with 100  $\mu$ l of 1M NaOH. The amount of remaining fibrin was quantified by measuring the 280 nm absorbance 15 of these reconstituted clots. The degree of fibrinolysis, which is a result of delta-plasminogen binding to fibrin, was plotted on the graph as a function of delta-plasminogen concentration (solid line). The dash line represents the best fit of experimental data to a binding equation.

Figure 9 shows a 8-25% gradient SDS-PAGE of starting delta-plasminogen 20 under non-reduced (Lane 1) and reduced conditions (Lane 2) and final delta-plasmin preparation, also under non-reduced (Lane 3) and reduced (Lane 4) conditions.

Figure 10 shows schematic diagrams of plasmin, mini-plasmin, micro-plasmin, and delta-plasmin, along with a corresponding characterization of enzymatic activity ( $k_{cat}$  and  $K_M$  with respect to substrate S-2251 (D-Val-Leu-Lys-p-nitroanilide, 25 DiaPharma Group, Inc., West Chester, OH)).

Figure 11 is a graphic representation of delta-plasmin-induced lysis of retracted whole -blood clots. Each clot (0.8x7 cm) was injected with a 1 ml volume of vehicle (acidified saline, pH 3.6), plasmin (1.0 mg/ml), or delta-plasmin (0.44 mg/ml), and clot dissolution was allowed to proceed at 37 °C for 1 hour.

30

### Description of the Invention

In order to provide a simple, non-glycosylated molecule having the fibrin- and antiplasmin-binding properties of full-length plasmin, the present invention provides a

deletion mutant of plasminogen. In this mutant, referred to herein as delta-plasminogen, at least a portion of the native amino acid sequence between a domain homologous to kringle 1 and the activation site is deleted. In one aspect, the domain homologous to the native kringle 1 domain of human plasminogen can be directly attached to the serine protease portion of plasminogen, or an homologous, functional analog thereof, with substantially only the intervening native sequence containing the plasminogen activation site remaining between the domains.

Delta-plasmin(ogen) according to the present invention can be characterized by: lower molecular weight (37,198 Da) of delta-plasmin can result in increased specific activity (per mg of protein); the lack of at least two glycosylation sites found in the native protein (see Figure 3), combined with the relatively low molecular weight, can facilitate recombinant production of this protein using relatively inexpensive bacterial and yeast expression systems; delta-plasminogen can be activated by plasminogen activators tPA, urokinase, and streptokinase; the presence of the domain homologous to native kringle 1 preserves the fibrin-binding properties of plasmin which can be important for thrombolytic efficacy; presence of  $\alpha_2$ -antiplasmin-binding sites on the domain homologous to kringle 1 can allow delta-plasmin to be inhibited rapidly by this physiological inhibitor of plasmin (a feature which can prevent bleeding); the smaller size of delta-plasmin can facilitate its inhibition by  $\alpha_2$ -macroglobulin, further lessening the chance of bleeding complications relative to native plasmin. In particular embodiments, the absence of kringle 5, which retains the primary binding site for intact, undigested fibrin(ogen), can allow use of delta-plasmin with reduced depletion of circulating fibrinogen.

Generally, the invention provides recombinant plasmin(ogen) molecules having a single kringle region N-terminal to the activation site and serine protease domain, having certain advantages relative to mini-plasmin(ogen). Although the delta-plasminogen polypeptides of the invention only have one kringle region, as such, N-terminal to the activation site, some embodiments include additional sequences N-terminal to the activation site. Additional N-terminal sequences can be derived from those of native kringle regions of plasminogen.

The N-terminal kringle domains of the present invention include kringle sequences of kringles 1 and 4 of native plasmin(ogen) and functional equivalents thereof. In particular, see the discussion below which provides guidance regarding

preservation of function in polypeptide variants, including preservation of residues participating in or influencing lysine-binding.

### Definitions

5        The terms "domain" and "region" of a polypeptide are generally synonymous as used herein, unless otherwise indicated to the contrary. When recited together with well-recognized structural or functional designations such as "kringle" or "serine protease," etc., such terms will introduce a polypeptide feature relating to at least some characteristic(s) commonly recognized and understood to be associated with the  
10      polypeptide structures corresponding to such designations.

A "cultured host cell," as used herein, refers to a prokaryotic or eukaryotic cell that contains heterologous DNA that has been introduced into the cell by any means, *e.g.*, electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and the like.

15        "Heterologous" as used herein means "of different natural origin" or representing a non-natural state. For example, if a cultured host cell is transformed with a DNA or gene derived from another organism, particularly from another species, that gene is heterologous with respect to that cultured host cell and also with respect to descendants of the cultured host cell which carry that gene. Similarly,  
20      "heterologous" refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, *e.g.*, a different copy number or under the control of different regulatory elements.

A "vector" molecule is a nucleic acid molecule into which heterologous nucleic acid can be inserted which can then be introduced into an appropriate cultured host cell. Vectors preferably have one or more origins of replication, and one or more sites into which the recombinant DNA can be inserted. Vectors often have convenient means by which cells with vectors can be selected from those without, *e.g.*, they encode drug resistance genes. Common vectors include plasmids, viral genomes, and (primarily in yeast and bacteria) "artificial chromosomes."

30        As used herein, the term "transcriptional control sequence" refers to nucleic acid sequences, such as initiator sequences, enhancer sequences and promoter sequences, which induce, repress, or otherwise control the transcription of protein encoding nucleic acid sequences to which they are operably-linked.

The term "polypeptide" is used interchangeably herein with the terms "peptide" and "protein."

The terms "polynucleotide" and "nucleic acid" are used interchangeably herein, and can refer to any nucleic acid that contains the information necessary for 5 the purpose indicated by the context. That is, the nucleic acid can be DNA or RNA, either single stranded or double stranded, or other nucleic acid, as long as the polymer is capable of representing the appropriate information, *e.g.*, in relation to an encoded peptide, and can include complementary sequences, *e.g.*, sense strands and anti-sense strands of nucleic acids polymers.

10 The term "variant" of a polypeptide refers to an amino acid sequence that is altered by one or more amino acids. The variant can have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, *e.g.*, replacement of leucine with isoleucine. Alternatively, a variant can have "non-conservative" changes, *e.g.*, replacement of a glycine with a tryptophan. Analogous 15 minor variation can also include amino acid deletion or insertion, or both. A particular form of a "variant" polypeptide is a "functionally equivalent" polypeptide, *i.e.*, a polypeptide which exhibits substantially similar *in vivo* or *in vitro* activity as the examples of the polypeptide of invention, as described in more detail below. Guidance in determining which amino acid residues can be substituted, inserted, or 20 deleted without eliminating biological or immunological activity can be found using computer programs well-known in the art, for example, DNASTAR software (DNASTAR, Inc., Madison, WI). Further, specific guidance is provided below, including that provided within the cited references which are fully incorporated herein by reference.

25 The terms "N-terminal" and "C-terminal" are used herein to designate the relative position of any amino acid sequence or polypeptide domain or structure to which they are applied. The relative positioning will be apparent from the context. That is, an "N-terminal" feature will be located at least closer to the N-terminus of the polypeptide molecule than another feature discussed in the same context (the other 30 feature possibly referred to as "C-terminal" to the first feature). Similarly, the terms "5'-" and "3'-" can be used herein to designate relative positions of features of polynucleotides.

The delta-plasminogen/plasmin polypeptides referred to herein as having a N-terminal domain "homologous to a kringle domain of native human plasminogen" exhibit structural and functional characteristics similar to native kringle domains of plasminogen. Further, the delta-plasminogen/plasmin polypeptides referred to herein as having a N-terminal domain "homologous to kringle 1" exhibit characteristics similar to native kringle 1, at least to the extent that the polypeptides can have a higher affinity for  $\omega$ -aminocarboxylic acids (and functional homologs such as *trans*-4-aminomethylcyclohexane-1-carboxylic acid, a cyclic acid) than kringle 5. See, e.g., Chang, Y., *et al.*, *Biochemistry* 37:3258-3271 (1998), incorporated herein by reference, for conditions and protocols for comparison of binding of isolated kringle domain polypeptides to 5-aminopentanoic acid (5-APnA); 6-aminohexanoic acid (6-AHxA), also known as  $\epsilon$ -aminocaprylic acid ( $\epsilon$ ACA); 7-aminoheptanoic acid (7-AHpA); and *trans*-4-aminomethylcyclohexane-1-carboxylic acid (t-AMCHA).

References to kringle domains "homologous to kringle 4" are defined similarly, as noted above regarding the phrase "homologous to kringle 1." That is, they exhibit functional characteristics similar to kringle 1 of native human plasminogen as discussed above. These polypeptides also bind immobilized lysine as described above.

The polypeptides of the invention bind immobilized lysine. As used herein, the phrase "binding immobilized lysine" means that the polypeptides so characterized are retarded in their progress relative to mini-plasminogen when subjected to column chromatography using lysine-SEPHAROSE as the chromatographic media. Typically, the polypeptides of the invention can be eluted from such chromatographic media (lysine affinity resins) using solutions containing the specific ligand, e.g.,  $\epsilon$ ACA, as eluants.

Further, in addition to Chang *et al.*, *supra*, other references can be consulted by those of skill in the art to determine which residues can be varied by conservative or non-conservative substitution, deletion or addition to yield a deletion mutant within the scope of the present invention. For example, the following references provide information regarding particular residues of the native kringle domains that may be important for binding of  $\omega$  aminocarboxylic acids: U.S. Pat. No. 6,538,103 to Ji, *et al.*; U.S. Pat. No. 6,218,517 to Suzuki; Douglas, J.T., *et al.*, *Biochemistry* 41(10):3302-10 (2002); Zajicek, J., *et al.*, *J. Mol. Biol.*, 301(2):333-47 (2000); Lee,

H., *et al.*, *Arch Biochem Biophys.*, 375(2):359-63 (2000); Castellino, F. and S. McCance, *Ciba Found Symp.* 212:46-60 (1997); McCance, S., *et al.*, *J. Biol. Chem.*, 269:32405-32410 (1994); Rejante, M.R. and M. Llinas, *Eur. J. Biochem.*, 221(3):939-49 (1994); Wu, T.P., *et al.*, *Blood Coagul. Fibrinolysis*, 5(2):157-66 (1994); Hoover, 5 C.J., *et al.*, *Biochemistry*, 32(41):10936-43 (1993); Menhart, N., *et al.*, *Biochemistry*, 32:8799-8806 (1993); Thewes, T., *et al.*, *J. Biol. Chem.*, 265 (7):3906-3915 (1990); Novokhatny, V., *et al.*, *Thromb Res.*, 53(3):243-52 (1989); Motta, A., *et al.*, *Biochemistry*, 26(13):3827-36 (1987); Novokhatny, V., *et al.*, *J. Mol. Biol.*, 179:215-232 (1984); Lerch, P.G., *et al.*, *Eur. J. Biochem.*, 107(1):7-13 (1980); Sottrup-Jensen, 10 L., *et al.*, *Prog. Chem. Fibrinol. Thrombol.*, 3:191-209 (1978); and Wiman, B. and D. Collen, *Nature* 272, 549-545 (1978), all incorporated herein by reference in their entirety.

Because the present inventors have recognized that a valuable, simplified plasmin(ogen) molecule can be prepared having an N-terminal kringle domain having 15 advantageous functional characteristics (which can be evaluated, in part, by testing for the binding of immobilized lysine as described herein), the present invention can encompass other fibrin-binding domains or regions N-terminal to the activation site. For example, the invention can include polypeptides in which the serine protease domain of plasmin is attached to a fibrin-binding kringle selected from a group 20 including, but not limited to, kringle 4 of human plasminogen, kringle 2 of tPA, or a kringle of apolipoprotein (a). Further, the invention can include polypeptides in which a serine protease domain of plasmin is attached to any other known fibrin-binding modules, such as the "finger" domain of tPA or fibronectin, or the FAB fragment of fibrin-specific IgG.

25 In particular embodiments, residues at certain positions of the N-terminal kringle domain of delta-plasminogen are conserved relative to kringle 1 of native human plasminogen. These can be residues at positions associated with lysine binding, and include Pro136-Pro140, Pro143-Tyr146, and Arg153-Tyr156 (positions numbered as shown in Figure 3). Some embodiments of the delta-plasminogen of the 30 invention can have Arg at position 153. In other embodiments, the specific positions of the named residues can vary somewhat while still being present in the polypeptide at structurally and functionally analogous positions (*i.e.* relative to the kringle structure of the N-terminal domain; see Chang, Y., *et al.* as discussed above). In

some embodiments, the N-terminal kringle region of the delta-plasmin(ogen) polypeptide has at least one residue greater percent identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen.

Additionally, particular embodiments of the invention can be characterized 5 functionally by contrast to mini-plasmin(ogen) which has a similar domain composition, *i.e.*, kringle-serine protease (K-SP) (see Sottrup-Jensen, L., *et al.*, Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, (Eds: J. F. Davidson, *et al.*) Raven Press, New York (1978)). In preferred embodiments, the delta-plasmin of 10 the invention exhibits an increased rate of inhibition by  $\alpha_2$ -antiplasmin, *e.g.*, as much as about one or two orders of magnitude faster than the rate of inhibition of mini-plasmin. Further, in particular embodiments, delta-plasmin binds immobilized lysine 15 (*e.g.*, lysine-SEPHAROSE).

Characterization of the kringle domain of delta-plasminogen as "N-terminal" means only that the domain is present N-terminal to the activation site and does not 15 mean that additional amino acids residues N-terminal to the domain itself are not present. Further, the number and identity of residues interposed between the domain homologous to kringle 1 and the activation site of plasminogen can be varied without departing from the scope of the present invention. One of skill in the art will be able 20 to determine these variations that achieve the benefits of the invention (kringle 1-like binding of  $\omega$  aminocarboxylic acids, without substantial increase in size of the deletion mutant or introduction of potentially problematic glycosylation sites) without undue experimentation based on the disclosure herein and the references cited herein for guidance regarding kringle 1 function and structure.

Accordingly, the invention relates to polynucleotides, polypeptides, 25 recombinant methods for producing the polypeptides, vectors containing the polynucleotides, expression systems for producing the polypeptides, and cultured host cells comprising such expression systems.

As noted, in one aspect, the invention relates to a polynucleotide encoding the 30 polypeptide disclosed herein or a polypeptide having conservative amino acid substitutions thereof. Guidance regarding selection of "conservative" amino acid substitutions is provided in more detail below. In one embodiment, the polynucleotide is DNA.

In another aspect, the invention relates to a method of making a vector comprising inserting the polynucleotide of the invention into a vector. In another aspect, the invention relates to a vector produced by the method of the invention.

5 In another aspect, the invention relates to a method of making a cultured host cell comprising introducing the vector of the invention into a cultured host cell. In another aspect, the invention relates to a cultured host cell produced by the method of the invention.

10 In another aspect, the invention relates to an isolated polypeptide of the invention, produced by a method comprising: (a) introducing a vector comprising a polynucleotide encoding the polypeptide into a cultured host cell; (b) culturing the host cell; and (c) recovering the polypeptide. In another aspect, the invention relates to a method for producing a polypeptide comprising: (a) culturing the host cell of the invention under conditions that the vector is expressed; and (b) recovering the polypeptide.

15 In another aspect, the invention relates to cells containing at least one polynucleotide of the invention.

In one embodiment, the polynucleotide comprises the nucleotide sequence as shown in SEQ ID NO:1. In another embodiment, the polypeptide comprises the amino acid sequence as shown in SEQ ID NO:2.

20

### Polynucleotides

The polynucleotides of the invention include variants which have substitutions, deletions, and/or additions which can involve one or more nucleotides. The variants can be altered in coding regions, non-coding regions, or both. 25 Alterations in the coding regions can produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the delta-plasmin(ogen) protein or portions thereof. Also especially preferred in this regard are conservative substitutions (see below).

30 Further embodiments of the invention include nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to (a) a nucleotide sequence encoding the delta-plasminogen polypeptide having the complete amino acid

sequence in SEQ ID NO: 2; (b) a nucleotide sequence encoding the delta-plasminogen polypeptide having the amino acid sequence in SEQ ID NO:2; and (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b) above.

By a polynucleotide having a nucleotide sequence at least, for example, 95% 5 “identical” to a reference nucleotide sequence encoding a delta-plasminogen polypeptide is intended that the nucleotide sequence of the polynucleotide be identical to the reference sequence except that the polynucleotide sequence can include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the delta-plasminogen polypeptide. In other words, to obtain a 10 polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence can be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence can be inserted into the reference sequence. These mutations of the reference sequence can occur at the 5' or 3' 15 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As noted above, two or more polynucleotide sequences can be compared by determining their percent identity. Two or more amino acid sequences likewise can 20 be compared by determining their percent identity. The percent identity of two sequences, whether nucleic acid or peptide sequences, is generally described as the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100. An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, 25 Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, *Nucl. Acids Res.* 14(6):6745-6763 (1986). An implementation of this 30 algorithm for nucleic acid and peptide sequences is provided by the Genetics Computer Group (Madison, Wis.) in their BESTFIT utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package

Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, Wis.).

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules 5 having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of the nucleic acid sequence shown in SEQ ID NO: 1 will encode a delta-plasminogen polypeptide. In fact, because degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing any functional assays or measurements described 10 herein. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having delta-plasminogen polypeptide activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a 15 second aliphatic amino acid).

Recently, advances in the synthetic production of longer polynucleotide sequences have enabled the synthetic production of nucleic acids encoding significantly longer polypeptides without the use of traditional cloning techniques. Commercial providers of such services include Blue Heron, Inc., Bothell, WA 20 (<http://www.blueheronbio.com>). Technology utilized by Blue Heron, Inc. is described in U.S. Patent Nos. 6,664,112; 6,623,928; 6,613,508; 6,444,422; 6,312,893; 4,652,639; U.S. Published Patent Application Nos. 20020119456A1; 20020077471A1; and Published International Patent Applications (Publications Nos) WO03054232A3; WO0194366A1; WO9727331A2; and WO9905322A1, all 25 incorporated herein by reference.

Of course, traditional techniques of molecular biology, microbiology, and recombinant nucleic acid can also be used to produce the polynucleotides of the invention. These techniques are well known and are explained in, for example, Current Protocols in Molecular Biology, F. M. Ausubel, ed., Vols. I, II and III (1997); 30 Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); DNA Cloning: A Practical Approach, D. N. Glover, ed., Vols. I and II (1985); Oligonucleotide Synthesis, M. L. Gait, ed. (1984); Nucleic Acid Hybridization, Hames and Higgins,

eds. (1985); *Transcription and Translation*, Hames and Higgins, eds. (1984); *Animal Cell Culture*, R. I. Freshney, ed. (1986); *Immobilized Cells and Enzymes*, IRL Press (1986); Perbal, "A Practical Guide to Molecular Cloning"; the series, *Methods in Enzymology*, Academic Press, Inc. (1984); *Gene Transfer Vectors for Mammalian Cells*, J. H. Miller and M. P. Calos, eds., Cold Spring Harbor Laboratory (1987); and *Methods in Enzymology*, Wu and Grossman and Wu, eds., respectively, Vols. 154 and 155, all incorporated herein by reference.

#### **Vectors and Cultured Host Cells**

The present invention also relates to vectors which include the isolated nucleic acid molecules of the present invention, cultured host cells which are genetically engineered with the recombinant vectors, and the production of the delta-plasmin(ogen) polypeptides by recombinant techniques.

Recombinant constructs can be introduced into cultured host cells using well-known techniques such as infection, transduction, transfection, transvection, electroporation and transformation. The vector can be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors can be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing cultured host cells.

The polynucleotides can be joined to a vector containing a selectable marker for propagation in a cultured host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it can be packaged *in vitro* using an appropriate packaging cell line and then transduced into cultured host cells.

Preferred are vectors comprising *cis*-acting control regions to the polynucleotide of interest. Appropriate *trans*-acting factors can be supplied by the cultured host, supplied by a complementing vector or supplied by the vector itself upon introduction into the cultured host.

In certain embodiments in this regard, the vectors provide for specific expression, which can be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids,

bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.

5 DNA inserts should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a  
10 ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one  
15 selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate cultured hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells;  
20 insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described cultured host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen Inc., Valencia, CA; pBS vectors, PHAGESCRIPT vectors,  
25 BLUESCRIPT vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene, LaJolla, CA; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia (now Pfizer, Inc., New York, NY). Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other  
30 suitable vectors will be readily apparent to the skilled artisan.

Bacterial promoters suitable for use in the present invention include the *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters, and the trp promoter. Suitable eukaryotic promoters include the

CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

5       Introduction of a vector construct into the cultured host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods In Molecular Biology*, 2<sup>nd</sup> Edition (1995).

10      Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given cultured host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late  
15     side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

20      For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals can be incorporated into the expressed polypeptide. The signals can be endogenous to the polypeptide or they can be heterologous signals.

25      The polypeptide can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus of the polypeptide to improve stability and persistence in the cultured host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to the polypeptide to facilitate purification. Such regions can be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or  
30     excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP 0 464 533 A1 (Canadian counterpart, 2,045,869) discloses fusion proteins comprising

various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties. On the other hand, for some uses it 5 would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery for example, human proteins have been fused with Fc portions for the 10 purpose of high-throughput screening assays (such as hIL5-receptor, to identify antagonists of hIL-5). See, Bennett, D., *et al.*, *J. Molecular Recognition*, 8:52-58(1995) and Johanson, K. *et al.*, *J. Biol. Chem.*, 270(16):9459-9471 (1995).

Delta-plasminogen protein can be recovered and purified from recombinant cell cultures by well-known methods including those specifically described in the 15 examples herein. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic cultured host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. In addition, polypeptides of the invention can also include an initial modified methionine residue, 20 in some cases as a result of host-mediated processes.

### Polypeptides

The polynucleotides of the invention include those encoding variations and particular examples of the polypeptides of the invention. For example, guidance 25 concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions. Although any number of substitutions within the scope of the invention can be obtained by 30 application of such general principles, for specific guidance regarding substitutions, the references cited herein regarding structure and function of kringle 1 domains can be consulted by one of skill in the art.

It will further be appreciated that, depending on the criteria used, the exact "position" of the kringle 1, activation site, and serine protease domains of the delta-plasminogen polypeptide can differ slightly in particular variations within the scope of the present invention. For example, the exact location of the kringle 1 domain relative 5 to the activation site can vary slightly and/or the sequence N-terminal to the kringle 1 domain can vary in length. Thus, the invention includes such variations of the delta-plasminogen polypeptide which exhibit delta-plasminogen polypeptide activity as disclosed herein. Such variants include deletions, insertions, inversions, repeats, and substitutions. As indicated above, guidance concerning which amino acid changes are 10 likely to be phenotypically silent can be found in Bowie, J. U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

Thus, fragments, derivatives or analogs of the polypeptide of SEQ ID NO: 2 can be (i) ones in which one or more of the amino acid residues (e.g., 3, 5, 8, 10, 15 or 15 20) are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue). Such substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) ones in which one or more of the amino acid residues includes a substituent group (e.g., 3, 5, 8, 10, 15 or 20), or (iii) ones in which the mature polypeptide is fused with another compound, such as a 20 compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) ones in which the additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be 25 within the scope of those skilled in the art from the teachings herein.

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, 30 the number of substitutions for any given delta-plasminogen polypeptide will not be more than 50, 40, 30, 25, 20, 15, 10, 5 or 3.

Amino acids in the delta-plasminogen polypeptide of the present invention that are essential for function can be identified by methods known in the art, such as site-

directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity, *e.g.*, as shown in the examples provided herein. Sites 5 that are critical for ligand binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith, *et al.*, *J. Mol. Biol.* 224:399-904 (1992) and de Vos, *et al.* *Science* 255:306-312 (1992)). Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other 10 biological activities can still be retained.

It is also contemplated that polypeptides useful in production of the "isolated polypeptides" of the invention can be produced by solid phase synthetic methods. See Houghten, R. A., *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985); and U.S. Pat. No. 4,631,211 to Houghten *et al.* (1986).

15 The polypeptides of the present invention can be provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant cultured host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, 20 partially or substantially, from a recombinant cultured host.

25 Polypeptides having an amino acid sequence of an indicated percent identity to a reference amino acid sequence of a delta-plasminogen polypeptide can be determined using the methods, including computer-assisted methods, indicated above regarding polynucleotides. Polypeptide amino acid sequences are examined and compared just as are the nucleotide sequences in the foregoing discussion. One of skill in the art will recognize that such concepts as the molecular endpoints discussed for polynucleotides will have direct analogs when considering the corresponding use 30 of such methods and programs for polypeptide analysis. For example, the manual corrections discussed regarding polynucleotides refer to 5' and 3' endpoints of nucleic acids, but the same discussion will be recognized as applicable to N-termini and C-termini of polypeptides.

The invention encompasses delta-plasminogen polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation,

phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, *etc.* Any of numerous chemical modifications can be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, 5 chymotrypsin, papain, *S. aureus* V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; *etc.*

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid 10 backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition of an N-terminal methionine residue as a result of vectors and constructs adapted for expression of delta-plasminogen polypeptides in prokaryotic cultured host cells. The polypeptides can also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of 15 the protein.

#### **Pharmaceutical Compositions and Methods of Treatment**

Delta-plasmin(ogen) can be formulated for therapeutic use in accordance with the methods and compositions described in US 2003/0012778 A1; and Novokhatny, 20 V., *et al.*, *J. Thromb. Haemost.* 1(5):1034-41 (2003), both incorporated herein by reference. For example, a low-pH (from about 2.5 to about 4), low-buffering capacity buffer can be used for formulation of delta-plasmin. Additionally, other methods and formulations known to those of skill in the art, as practiced with plasmin, mini-plasmin, and/or micro-plasmin, can be used to formulate the delta-plasmin of the 25 invention for therapeutic administration.

The delta-plasmin(ogen) can be used to treat a variety of thrombotic diseases or conditions, for example, according to the methods as described in U.S. Patent No. 6,355,243; and published U.S. Patent Application Nos. US 2003/0026798 A1; US 2003/0175264 A1, all incorporated herein by reference. Again, as with the possible 30 pharmaceutical formulations applicable to delta-plasmin, delta-plasmin can also be administered therapeutically by methods known in the art, for example, those that may be currently practiced with plasmin, mini-plasmin, and/or micro-plasmin.

## EXAMPLES

### Expression Vector Design

The amino acid sequence for delta-plasminogen is shown in SEQ ID NO:2. A 5 putative sequence encoding delta-plasminogen was codon-optimized for *E. coli* expression and mRNA stability to produce the DNA sequence as shown in SEQ ID NO:1.

This DNA was chemically synthesized (Blue Heron, Inc.) and inserted into the NdeI and BamH1 sites of *E. coli* expression vector pET22b(+) (Novagen; Madison, WI) in 10 order to produce cytosolic protein. This construct produces delta-plasminogen with an additional, non-native N-terminal methionine. (pET-22b(+) = pET Expression System 22b (Cat. No. 70765), EMD Biosciences, Inc., Novagen Brand, Madison, WI; see <http://www.emdbiosciences.com> product information section regarding pET-22b for details regarding vector).

15

### Delta-Plasminogen Expression and Purification

The DNA encoding delta-plasminogen sequence was transformed into a variety of cells, and protein over-expression following induction by 1mM IPTG (isopropyl-beta-D-thiogalactopyranoside) was analyzed by SDS-PAGE. Cell type 20 BL21(DE3) RIL (Stratagene, La Jolla, CA) cells, engineered to express rare *E. coli* tRNAs coding for Arg, Ile, and Leu, were used for production of delta-plasminogen.

Production of delta-plasminogen was confirmed in larger scale expression in which cells were lysed and both soluble protein and purified inclusion bodies were examined by SDS-PAGE. BL21(DE3) RIL cells produced significant delta-plasminogen protein in the form of inclusion bodies. Expression estimates were 50-25 80 mg/L cell culture.

The following typical protocol has been used for expression of delta-plasminogen:

A single colony of BL21(DE3) RIL cells containing the delta-plasminogen 30 vector was used to inoculate 5 ml of LB/ampicillin (100 µg/ml) /chloramphenicol (50 µg/ml) and was incubated for 8 hours at 37°C on a shaker. After that, a 50 µl-aliquot was taken form the cultured bacterial suspension for further growth in fresh media. The procedure was repeated after 16 hours with 6 ml of bacterial culture and 250 ml

of the media. Cultures were grown at 37°C with shaking to an OD600 nm of ~ 1.0, and IPTG was added to 1 mM final concentration. Cultures were grown for an additional 5 hours. Cells were harvested by centrifugation at 5,000 x g and cell pellets were dissolved in 20 mM Tris pH 8.0 containing 20 mM EDTA and frozen at -80 °C.

5 To purify delta-plasminogen, cell pellets were thawed and buffer added until the solution volume was approximately 1/20th that of the original cell culture volume. After that, lysozyme was added to a final concentration of 0.5 mg/ml and the cells were stirred rapidly at 4°C for 10 - 15 minute. Then, Triton X-100 was added to 1% final concentration and stirring continued for another 10 min. DNase I (0.05 mg/ml) 10 and MgCl<sub>2</sub> (2.5 mM) were added and stirring was continued at 4°C for 30 minutes or until the solution was no longer viscous. The final solution was centrifuged at 4°C for 30 min at 15,000 x g and the supernatant was discarded.

15 The cell pellet was washed three times with wash solution (50 mM Tris-HCl, pH 7.4 containing 10 mM EDTA, 1 % Triton-X-100, and 0.5 M urea), and the final pellet was dissolved in 40 ml of extraction buffer (PBS, pH 7.4 containing 10 mM EDTA, 20 mM DTT, and 6 M guanidine-HCl) and stored at 4 °C overnight. After 16 hours, the solution was centrifuged for 30 minutes at 15,000 x g to remove solids and the supernatant was slowly added to the refolding solution (50 mM Tris-HCl, pH 8.3, 3.5 M guanidine HCl, 0.5 M arginine HCl, 10 mM EDTA, 3 mM GSH, 0.3 mM 20 GSSG) while stirring at 4°C. The refolding procedure was carried out at protein concentration of 0.03 mg/ml or less.

25 The refolding solution was kept for 2 days at 4°C undisturbed and then dialyzed against an 8-fold volume of 0.1 M Tris-HCl pH 8.0 containing 10 mM EDTA, 0.15 M NaCl, 0.15 M arginine-HCl, over a period of 8-10 hours with frequent changes of the buffer solution.

30 The protein solution was then removed from dialysis and concentrated using AMICON filters with the membrane cut-off of 10 kDa to approximately 10 -20 ml and dialyzed overnight versus a 100-fold volume of 0.1 M Tris pH 8.0 containing 10 mM EDTA, 0.15 M NaCl. This material was centrifuged to remove particulates, then passed over lysine affinity resin (Lysine-SEPHAROSE 4B; Amersham Biosciences, Piscataway, NJ). Delta-plasminogen was eluted from the resin using Tris-buffered saline, pH 8.0 containing 0.2 M epsilon aminocaproic acid (εACA).

Typically, 80 mg of inclusion bodies could be isolated from 1 liter of cell culture and 40 mg could be eluted in the lysine-SEPHAROSE chromatography step.

### Properties of Delta-Plasminogen

5 Purified delta-plasminogen appeared as a single band in the 35-40 kDa region by SDS-PAGE analysis of reduced (dithiothreitol-treated) and non-reduced protein (See Fig. 5). Its exact molecular mass, determined by MALDI mass-spectrometry, was 37,089 Da, very close to the expected value of 37,198 Da.

10 To test whether delta-plasminogen ( $\Delta$ Pg) could be activated into delta-plasmin, delta-plasminogen was incubated with urokinase (1:1000 molar ratio), and the increase in serine protease activity was monitored by measuring the increase in the rate of S-2251 hydrolysis (S-2251 = D-Val-Leu-Lys-p-nitroanilide, DiaPharma Group, Inc., West Chester, OH). As seen in Fig. 6, a parabolic increase in activity typical for the coupled reaction of activation (zymogen is converted into active enzyme (1); and 15 enzyme cleaves the chromogenic substrate (2)) is observed. Activation of delta-plasminogen to delta-plasmin was complete within 3 minutes under these conditions. Very similar results were obtained with tPA and streptokinase.

20 The kinetics for the urokinase activation of delta-plasminogen were compared to those for full-length plasminogen using the method of Wohl et al. (Wohl, R.C., Summaria, L., Arzadon, L., and Robbins, K.C.; *J. Biol. Chem.* 253: 1402-1407 (1978), fully incorporated by reference). For this purpose, 5.8 nM urokinase was added to solutions containing various concentrations of plasmin species in the presence of 1 mM S-2251 substrate at 37 °C, pH 7.5. The increase in absorbance at 405nm was monitored and the accelerating rate of S-2251 product formation was 25 calculated using a parabolic equation where rate =  $k \cdot t^2$ . Data were fit to a Michaelis-Menten kinetic model using Lineweaver-Burk analysis, resulting in the values below:

Table 1. Kinetics for the urokinase activation of delta-plasminogen.

Species:	K <sub>m</sub> (μM)	k <sub>cat</sub> (min <sup>-1</sup> )	k <sub>cat</sub> /K <sub>m</sub> (μM <sup>-1</sup> min <sup>-1</sup> )
Delta-plasminogen	30 +/- 5	80 +/- 10	2.67
Plasminogen	1.2 +/- 0.1	2.3 +/- 0.3	1.92

Full-length plasminogen was activated well by urokinase, with  $K_m$  values similar to those found in the literature (1.7  $\mu\text{M}$ ; Wohl, R.C., Summaria, L., and Robbins, K.C.; *J. Biol. Chem.* 255(5): 2005-2013 (1980)) and equivalent  $k_{\text{cat}}$  values.

$K_m$  values for urokinase activation of delta-plasminogen were approximately 5 30-fold higher than for plasminogen, possibly indicating a lower affinity of urokinase for this mutant of plasminogen. At the same time, the  $k_{\text{cat}}$  value for activation of delta-plasminogen was much higher than for plasminogen: In spite of the above-mentioned differences in the  $k_{\text{cat}}$  and  $K_m$ , their ratio, or catalytic efficiency, is approximately the same for activation of the natural and recombinantly-modified 10 plasminogen species by urokinase. Thus, these data indicate that the presence of a "foreign" kringle 1 does not considerably affect the activation properties of the serine protease domain in delta-plasminogen.

In yet another activation experiment, delta-plasminogen was incubated with streptokinase, tPA, and urokinase and analyzed on reduced SDS-PAGE to observe the 15 conversion of the one-chain delta-plasminogen molecule in two-chain delta-plasmin (See Fig. 5, Lanes 3-5). In all three cases, two chains (~12 kDa kringle 1 and the ~ 25 kDa serine protease chain) of delta-plasmin could be seen, suggesting that delta-plasminogen indeed can be activated by all three plasminogen activators.

As expected, delta-plasminogen bound to lysine-SEPHAROSE via kringle 1 20 and could be eluted from the column by the gradient of  $\epsilon\text{ACA}$  as a single peak (See Figure 7). The ability of refolded delta-plasminogen to bind lysine-SEPHAROSE indicates that the kringle domain of the molecule is properly folded and the lysine-binding site is fully active.

To further confirm the functionality of kringle 1, the binding of  $\epsilon\text{ACA}$  to delta-plasminogen was measured by monitoring the associated changes in protein 25 fluorescence as described by Matsuka *et al.* (Matsuka, Y.V., Novokhatny, V.V., and Kudinov, S.A., *Eur. J. Biochem.* 190:93-97 (1990)) and Douglas *et al.* (Douglas, J.T., von Haller, P.D., Gehrmann, M., Llinas, M., and Schaller, J., *Biochemistry* 41:3302-3310(2002), all incorporated herein by reference). Binding of  $\epsilon\text{ACA}$  to kringle 1 of 30 delta-plasminogen results in a decrease in fluorescence, likely due to quenching of the tryptophan residues which are part of the lysine-binding site.

To monitor this process, 4  $\mu\text{l}$  to 16  $\mu\text{l}$  aliquots of a concentrated solution of  $\epsilon\text{ACA}$  were added to 2 ml of 5  $\mu\text{M}$  delta-plasminogen in 50 mM Tris buffer

containing 20 mM NaCl, pH 8.0, 25°C. The fluorescence was monitored at an excitation wavelength of 298nm and an emission wavelength of 340nm in a FLUOROMAX fluorescence spectrophotometer (Jobin Yvon, Inc., Edison, NJ); after each addition of  $\epsilon$ ACA, the solution was allowed to equilibrate until no further 5 changes in fluorescence were observed.

The resulting fluorescence values were corrected for dilution and plotted versus the concentration of  $\epsilon$ ACA over a range of 0 - 50  $\mu$ M  $\epsilon$ ACA. Data were fitted by non-linear regression to obtain a  $K_d$  of 11.1 +/- 2.3  $\mu$ M, in good agreement with literature values for kringle 1 affinity for  $\epsilon$ ACA of 3.2  $\mu$ M (Matsuka, *et al.*) and 13 10  $\mu$ M (Douglas, *et al.*).

One property of plasmin is its ability to bind fibrin. In order to determine whether delta-plasminogen retains the ability to interact with fibrin, its fibrin-binding properties were tested in a microtiter plate assay in which binding of delta-plasminogen to fibrin was assessed by its subsequent activation by tPA and resulting 15 clot lysis. For this purpose, 100  $\mu$ l of 5mg/ml fibrinogen was polymerized with thrombin in each well of a microtiter plate. Various concentrations of delta-plasminogen were added on top of the fibrin clots and incubated for 1 hour at 37°C. The plate was washed extensively with PBS while the fibrin clots were still intact and attached to the wells. After washing, a 0.1-mg/ml solution of tPA was added to each 20 well and the plate was incubated 2 hours at 37°C. As a result, some of the clots were completely dissolved and some were partially dissolved, while wells with very low amounts of delta-plasminogen and control wells remained practically intact. The degree of fibrinolysis was monitored by measuring the 280nm absorbance of remainders of the initial clots reconstituted in 1M NaOH. The absorbance values 25 were plotted as a function of delta-plasminogen concentration.

As seen in Fig. 8, the binding of delta-plasminogen to fibrin follows a classic, sigmoidal binding curve. Using this assay, it was found that delta-plasminogen binds fibrin with affinity comparable to that of full-length plasminogen and the  $C_{50}$  of this interaction (~0.2  $\mu$ M) is comparable to the  $K_d$  of fibrin-binding of full-length 30 plasminogen (Lucas, M.A., Fretto, L.J., and McKee, P.A.; *J. Biol. Chem.* 258(7): 4249-4256 (1983)). These experiments indicate that delta-plasminogen can bind fibrin.

Thus, the interaction of delta-plasminogen with lysine-SEPHAROSE, its ability to bind  $\epsilon$ ACA with the expected  $K_d$ , its ability to bind fibrin, its ability to be activated by all major plasminogen activators, and the potency of delta-plasmin toward the chromogenic plasmin substrate S-2251 all indicated that this molecule was 5 produced in the *E. coli* system in a fully functional form.

#### Delta-Plasmin Purification and Formulation

Delta-plasminogen, dialyzed against 0.1M Tris buffer, pH 8.0 containing 10 mM EDTA and 0.15 M NaCl, was activated to delta-plasmin using urokinase immobilized on SEPHAROSE 4B essentially as described previously for plasmin 10 (Marder, V.J., *et al.*, *Thromb Haemost.*, 86(3):739-45 (2001), incorporated by reference). Activation occurred at room temperature and was monitored in real time by the increase in S-2251 activity. Depending on the amount of delta-plasminogen, which varied from batch to batch (typically 1-2 mg/ml), incubation time was 30-60 min. Upon completion of activation, when the S-2251 activity reached a plateau, 15 urokinase-SEPHAROSE was filtered out and active delta-plasmin was captured on benzamidine-SEPHAROSE (Pharmacia). Delta-plasmin was eluted from the resin using low-pH buffer (0.2 M glycine, pH 3.0, 0.3 M NaCl, 0.2M  $\epsilon$ ACA).

The protein concentrations and S-2251 activity in elution fractions were measured. High specific activity fractions were pooled and dialyzed against multiple 20 changes of 0.15 M NaCl, pH 3.6 at 4°C. SDS-PAGE analysis of non-reduced delta-plasmin samples (see Fig. 9, Lane 3) shows that the purity of this material is usually more than 95%. Under reduced conditions (Fig. 9, Lane 4), besides the serine protease and the kringle chains, there are two faint bands above and below the kringle band. These bands represent auto-degradation products of the serine protease domain 25 which result from internal cleavages of its polypeptide chain; they are normally held together by disulfide bonds but become visible with PAGE under reducing conditions. The amount of auto-degradation products, which typically did not exceed 10%, was greatly reduced by conducting the benzamidine-SEPHAROSE purification step in batch mode instead of the column format.

Because delta-plasmin, similar to full-length plasmin, is prone to auto-degradation at physiological pH, pH 3.6 was chosen for the final formulation (acidified with acetic acid-saline). As shown previously for plasmin (Novokhatny, V.

et al., *J Thromb Haemost.*, 1(5):1034-41 (2003), incorporated by reference) and confirmed in experiments with delta-plasmin, this low buffering-capacity, low pH formulation not only allows safe storage of active plasmins for prolonged periods of time, but is also compatible with parenteral administration of these direct 5 thrombolytics. When mixed with plasma or neutral pH buffers, delta-plasmin is quickly re-activated.

### Enzymatic Properties of Delta-Plasmin

The amidolytic activity of delta-plasmin was examined using the plasmin 10 substrate D-Val-Leu-Lys-p-nitroanilide (S-2251) (DiaPharma, West Chester, OH). At pH 7.4, 25 °C in PBS buffer, the Michaelis-Menten constant (Km) for S-2251 was found to be 138  $\mu$ M (Table 2). The kcat for the preparation was found to be 510  $\text{min}^{-1}$ . Using 4-nitrophenyl 4-guanidinobenzoate hydrochloride (pNPGB) titration (Chase, T. and E. Shaw, *Methods Enzymol.* 197:20-27(1970)), the percent of functional active 15 sites was found to be 67%. Correcting kcat for percent active sites, a kcat of 755 +/- 45  $\text{min}^{-1}$  was determined. This value was very close to the value determined in the same assay for full-length plasmin, 760 +/- 23  $\text{min}^{-1}$  and for micro-plasmin (lacking all five kringle), 795 +/- 24  $\text{min}^{-1}$  (See Figure 9). These data indicate that presence 20 or absence of kringle does not affect the catalytic activity of the serine protease domain.

The rate of inhibition of delta-plasmin by  $\alpha_2$ -macroglobulin was measured using the method of Anonick et al. (Anonick, P., et al., *Thrombosis Res.* 59:449-462 (1990)). The inhibition rate was found to be  $7.6 +/- 0.6 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$  at 22 °C in PBS buffer.

25 The rate of inhibition of delta-plasmin by  $\alpha_2$ -antiplasmin was determined to be  $1.1 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$  using the method of Wiman and Collen (Wiman, B. and D. Collen, *Eur. J. Biochem.* 84:573-578 (1978)) in which plasmin and  $\alpha_2$ -antiplasmin are mixed then assayed for S-2251 activity at specific time points (Table 3). This value is comparable to reported values for plasmin of  $2.5 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$  (from Anonick, et al., 30 *Thrombosis Res.* 59:449 (1990)).

The same experiments conducted with micro-plasmin revealed  $\alpha_2$ -antiplasmin inhibition rates of  $1.8 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$  and  $3.1 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$  in two separate experiments. The rate of  $\alpha_2$ -antiplasmin inhibition of mini-plasmin (mini-plasmin domain

composition, K5-SP) was determined to be  $2.4 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ . These data are in reasonable agreement with literature values for micro- and mini-plasmin and show that inhibition of delta-plasmin by  $\alpha_2$ -antiplasmin is 40-fold faster than the inhibition of either micro-plasmin or mini-plasmin. Thus, these results indicate that delta-  
5 plasmin should be rapidly inhibited by  $\alpha_2$ -antiplasmin due to the presence of kringle 1 in its structure.

Overall, the data presented in this section show that the enzymatic and inhibitory properties of delta-plasmin are similar to full-length plasmin.

Table 2. Steady-state kinetic parameters for various plasmin species with substrate S-2251, in PBS buffer, pH 7.4, 25 °C.

	K <sub>m</sub>	k <sub>cat</sub>
plasmin	193 +/- 7 µM	760 +/- 23 min <sup>-1</sup>
mini-plasmin	160 +/- 30 µM	770 +/- 70 min <sup>-1</sup>
micro-plasmin	145 +/- 13 µM	795 +/- 24 min <sup>-1</sup>
delta-plasmin	138 +/- 5 µM	755 +/- 45 min <sup>-1</sup>

5 Table 3. Inhibition rates for various plasmin species and inhibitors were determined at 22°C in PBS buffer, pH 7.4.

	α <sub>2</sub> -macroglobulin	α <sub>2</sub> -antiplasmin
plasmin	6.5 +/- 0.5 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>	2.5 +/- 0.5 x 10 <sup>7</sup> M <sup>-1</sup> s <sup>-1</sup> (lit.)
mini-plasmin	7.5 +/- 0.3 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>	2.4 +/- 0.5 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>
micro-plasmin	7.8 +/- 0.6 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>	1.8 +/- 0.2 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>
delta-plasmin	7.6 +/- 0.6 x 10 <sup>5</sup> M <sup>-1</sup> s <sup>-1</sup>	1.0 +/- 0.1 x 10 <sup>7</sup> M <sup>-1</sup> s <sup>-1</sup>

Literature values are taken from Anonick, *et al.*, *Thrombosis Res.* 59:449(1990). All rates were measured according to the methods published in Anonick, *et al.*

10

#### *In Vitro* Thrombolytic Efficiency

The thrombolytic efficacy of delta-plasmin was tested in an *in vitro* model of catheter-assisted thrombolysis (Novokhatny, V. *et al.*, *J Thromb Haemost.*, 1(5):1034-41 (2003), incorporated by reference) using the following experimental protocol.

15

Fresh whole human blood was collected into 20 x 0.95 cm glass tubes and allowed to clot spontaneously without additives. Tubes were incubated for 20 hr at 37°C to allow full retraction. Retracted clots were separated from serum using USA Standard testing sieves D16 with 14 mesh, and their weights were determined. Blood clots were transferred into smaller diameter glass tubes in which the retracted clots fit tightly (0.8 x 7 cm). The averaged weight of the clots was ~3.6 g.

20

Single 1-ml doses of acidified saline, plasmin, or delta-plasmin were injected into the clot using a syringe. The clots were incubated for 1 hour at 37°C in a THELCO laboratory oven (Jouan, Inc., Winchester, VA). After the incubation, the clots were placed again on the sieve to remove the liquefied material and the weight of 5 the digested clots was measured. The extent of clot lysis was determined from the difference between the initial clot weight and the weight of residual clot and was expressed as a percent of clot weight reduction.

Figure 10 shows the results of the lysis experiments with delta-plasmin in this model. The infusion of single 0.44 mg (equivalent to 1 mg/ml of plasmin on a molar 10 basis) dose of delta-plasmin resulted in 36% clot weight reduction within 60 min. At the same time, the weight of the clots infused with saline decreased only by 4%. Plasmin (1.0 mg) resulted in 50% clot weight reduction in the same period. Thus, these data show that delta-plasmin exhibits thrombolytic potency and can be used as a direct thrombolytic agent.

**What is claimed is:**

1. A polynucleotide comprising a nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine.
2. The polynucleotide of claim 1, wherein the N-terminal kringle domain is homologous to kringle 1 or kringle 4 of native human plasminogen.
3. The polynucleotide of claim 1, wherein the encoded polypeptide is at least 90% or 95%, or 98% identical to the sequence shown in SEQ ID NO:2.
4. The polynucleotide of claim 1, wherein the encoded polypeptide is at least 98% identical to the sequence shown in SEQ ID NO:2.
5. The polynucleotide of claim 1, wherein the encoded polypeptide is the sequence shown in SEQ ID NO:2.
6. The polynucleotide of claim 1, wherein the nucleotide sequence of the polynucleotide is the sequence shown in SEQ ID NO:1 or a degenerate variant thereof.
7. The polynucleotide of claim 1, wherein the nucleotide sequence encodes a polypeptide having an N-terminal kringle domain homologous to the kringle 1 or kringle 4 domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen.
8. The polynucleotide of claim 1, wherein the nucleotide sequence encodes a polypeptide having a single N-terminal kringle domain at least 90% identical to the

kringle 1 or kringle 4 domain of native human plasminogen; and a C-terminal domain at least 90% identical to the activation site and serine protease domain of human plasminogen.

9. A polypeptide comprising a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen, wherein the polypeptide binds to immobilized lysine.

10. The polypeptide of claim 9, wherein the N-terminal kringle domain is homologous to kringle 1 or kringle 4 of native human plasminogen.

11. The polypeptide of claim 9, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by  $\alpha_2$ -antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by  $\alpha_2$ -antiplasmin.

12. The polypeptide of claim 11, wherein the rate of inhibition is at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin.

13. The polypeptide of claim 1, wherein the immobilized lysine is lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-hydrogel, lysine-cross-linked agarose.

14. The polypeptide of claim 13, wherein the immobilized lysine is lysine-cross-linked agarose.

15. The polypeptide of claim 1, wherein the polypeptide exhibits a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.

16. The polypeptide of claim 1, wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.

17. A polypeptide comprising a single kringle domain located N-terminal to a plasminogen activation site and plasminogen serine protease domain, wherein the kringle domain has at least one residue greater amino acid sequence identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen, and wherein conservative substitutions of the single kringle region relative to the native sequences of kringle 1 and 4 of human plasminogen are not considered as differing from the native sequences for purposes of the identity comparison with kringle 5.

18. The polypeptide of claim 17, wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO:2, and conservative substitutions thereof.

19. The polypeptide of claim 17, wherein the polypeptide has an arginine residue at a relative position analogous to that of position 76 of the amino acid sequence shown in SEQ ID NO:2.

20. An expression vector comprising a polynucleotide of claim 1.

21. A cultured cell comprising the expression vector of claim 20.

FIG. 1





FIG. 2



## FIG. 3

-19 1  
 MEHKEVVL~~LLL~~FLKGQGEPLDDYVNTQGASLFSVTKQLGAGSIEECAKCEEDEFTCRAFQ

78  
 YHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGN~~G~~NYRGTMSKT~~K~~NGITCQKWSST

136 143 153 162  
SPHRPRFSPATHPSEGLEN~~Y~~CRNP~~D~~NDPQGPWCYTTDPEKRYDYC~~D~~ILECEE~~E~~CMHCS~~G~~ENYDG  
kringle 1

KISKTMSGLECQAWDSQS~~PH~~AHGYIPS~~K~~FPN~~K~~LN~~K~~NYCRNP~~D~~REL~~R~~WCFTTD~~P~~NKRWE~~L~~CDIP  
kringle 2

RCTT~~PP~~SSGPTYQCL~~K~~GTGEN~~Y~~RGNVAVT~~V~~SGHTCQHWSAQTPHTHNRTPENF~~P~~CKNLDEN~~Y~~CR  
kringle 3

NPDGKRAPWC~~HT~~NSQVRWEYCKIPSCDSSPVSTEQLAP~~T~~APP~~E~~LT~~P~~VVQDCYHGDGQS~~Y~~RG~~T~~SS

TTTGKKCQS~~W~~SSMTPHRHQ~~K~~T~~P~~EN~~Y~~PNAGLT~~M~~NYCRNP~~D~~AD~~K~~GPWCFTTD~~P~~SVRWEYCNLKCS  
kringle 4

GTEASVVAPPVVLLPDVETPSEEDCMFGNGKGYRGKRATT~~V~~TGTPCQDWAAQE~~PH~~RHSIFT~~P~~E~~T~~  
kringle 5

542  
 N~~P~~RAGLEKNYCRNP~~D~~GDVGGPWCYTTN~~P~~R~~K~~LYDYCDV~~P~~QCAAPS~~F~~DCGK~~P~~QVE~~P~~KKCPGRVVGGC

VAHPHSWEWQVSLRTREGMHFCGGTLISPEWVL~~AA~~HCLEKSPRPSSYK~~V~~ILGAHOEVNEEPHVG  
EIEVSRI~~F~~LEP~~T~~R~~K~~DIA~~L~~L~~K~~SSPAV~~I~~TD~~K~~V~~I~~PA~~C~~L~~P~~S~~P~~N~~Y~~VAD~~R~~TECFIT~~G~~WGET~~Q~~TEGAGI

LKEAQLPV~~I~~ENKVGNRYEFLN~~G~~R~~V~~Q~~S~~TELCA~~G~~HLAGGTD~~S~~CQGD~~S~~GGPLVC~~F~~E~~K~~D~~K~~Y~~I~~LO~~G~~V~~T~~SW

791  
GLGCARP~~N~~KPGVYVR~~V~~SR~~F~~V~~T~~W~~I~~E~~G~~VMRNN (SEQ ID NO:4)

FIG. 4

HK1	<u>CKTGNGKNYR</u>	<u>GTMSKTKNGI</u>	<u>TCQKWSSTSP</u>	<u>HR-PRFSPAT</u>	<u>HPSEGLEENY</u>
HK2	<u>CMHCSGENYD</u>	<u>GKISKTMMSGI</u>	<u>ECQAWDSQSP</u>	<u>HA-HGYIPSK</u>	<u>FPNKNLKKNY</u>
HK3	<u>CLKGTGENYR</u>	<u>GNVAVTVSGH</u>	<u>TCQHWSAQTP</u>	<u>HT-HNRTPEN</u>	<u>FPCKNLDENY</u>
HK4	<u>CYHGDGQSYR</u>	<u>GTSSTTTGK</u>	<u>KCQSWSSMTP</u>	<u>HR-HQKTPEN</u>	<u>YPNAGLTMNY</u>
HK5	<u>CMFGNGKGYR</u>	<u>GKRATTVTGT</u>	<u>PCQDWAAQEP</u>	<u>HRHSIFTPET</u>	<u>NPRAGLEKNY</u>

(con't)

HK1	<u>CRNPNDNPQG</u>	<u>PWCYTTDPEK</u>	<u>RYDYCDILEC</u>	(SEQ ID NO:5)
HK2	<u>CRNPDR-E-LR</u>	<u>PWCFTTDPNK</u>	<u>RWELCDIPRC</u>	(SEQ ID NO:6)
HK3	<u>CRNPDGK-RA</u>	<u>PWCHTTNSQV</u>	<u>RWEYCKIPSC</u>	(SEQ ID NO:7)
HK4	<u>CRNPDAD-KG</u>	<u>PWCFTTDPSV</u>	<u>RWEYCNLKKC</u>	(SEQ ID NO:8)
HK5	<u>CRNPDGDVGG</u>	<u>PWCYTTNPRK</u>	<u>LYDYCDVPQC</u>	(SEQ ID NO:9)

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9







FIG. 10

**Plasmin:**


K<sub>m</sub> 193 +/- 7  $\mu$ M  
k<sub>cat</sub>: 760 min<sup>-1</sup>

**Mini-plasmin:**

K<sub>m</sub> 160 +/- 30  $\mu$ M  
k<sub>cat</sub>: 770 min<sup>-1</sup>

**Micro-plasmin:**


K<sub>m</sub> 145 +/- 13  $\mu$ M  
k<sub>cat</sub>: 795 min<sup>-1</sup>

**Delta-plasmin:**

K<sub>m</sub> 138 +/- 5  $\mu$ M  
k<sub>cat</sub>: 755 min<sup>-1</sup>

FIG. 11

Summary Graph - 10 clots, 3 donors



## SEQUENCE LISTING

<110> Talecris Biotherapeutics, Inc.  
Hunt, Jennifer A.  
Novokhatny, Valery

<120> Recombinantly Modified Plasmin

<130> B185 1240-PCT(8017)

<150> US 60/564,472  
<151> 2004-04-22

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 1008  
<212> DNA  
<213> Artificial Sequence

<220>

<223> polynucleotide comprising a nucleotide sequence  
encoding a polypeptide having a single N-terminal  
kringle domain homologous to a kringle domain of  
native human plasminogen

<400> 1

aaagtctatt tatctgaatg taaaacaggc aatggtaaaa actatcgccg taccatgtcc 60  
aaaacaaaaa acggtatcac ttgtcaaaaa tggtctagca cttcacccca tcgtcctcg 120  
ttctccctg cgacccatcc ctctgaaggc ctgcagaaa actactgcgg caaccccgat 180  
aatgatcctc aaggccatg gtgttatact accgatctg aaaaacgtt tgactattgc 240  
gatatcttag aatgcgcagc cccttcttt gattgcggca aaccacaagt tgaacccaag 300  
aaatgtccag gtcgtgttgt cggcggtt gttgcgcac cccacagtgc gccgtggcag 360  
gtctcattac gtacccgggt tggaatgcac ttttggcg gcactctcat ctcgccccaa 420  
tgggttctta cagctgcaca ctgtttggaa aaaagcccc gtccttctc ttataaagtt 480  
atcctcggcg cacatcaaga agtcaattt aacacctatg tacaagaaat cgaagtatct 540  
cgtttattcc tggaaaccgac tcgaaagac atgcattac ttaaactgtc ctcccccgct 600  
gtgatcaccg ataaaagtaat tcccgctgt ttaccttctc ctaattatgt tggcagat 660  
cgtacagaat gctttattac cggctgggt gaaactcaag gtactttgg tgcgggactc 720  
ctgaaagaag cacagttacc agtcatcgaa aacaaagtat gtaatcgcta cgaattctt 780  
aacggtcgtg ttcaatccac agaattgtgc gcagggtcatt tagcagggtt cactgatagc 840  
tgtcaagggtt attcagggtt tcctctcgta tggttcgaaa aagataaaat tattctgcaa 900  
ggcgtcacct ctgggggtt aggttgcgt cgtcccaata aacctgggtt atatgtacgt 960  
gtaagtctt ttgttacctg gattgaaggt gttatgcgga acaactaa 1008

<210> 2

<211> 335

<212> PRT

<213> Artificial Sequence

<220>

<223> a polypeptide having a single N-terminal  
kringle domain homologous to a kringle domain of  
native human plasminogen

<400> 2

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg  
 1 5 10 15  
 Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser  
 20 25 30  
 Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser  
 35 40 45  
 Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln  
 50 55 60  
 Gly Pro Trp Cys Tyr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys  
 65 70 75 80  
 Asp Ile Leu Glu Cys Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln  
 85 90 95  
 Val Glu Pro Lys Lys Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala  
 100 105 110  
 His Pro His Ser Trp Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly  
 115 120 125  
 Met His Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr  
 130 135 140  
 Ala Ala His Cys Leu Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val  
 145 150 155 160  
 Ile Leu Gly Ala His Gln Glu Val Asn Leu Glu Pro His Val Gln Glu  
 165 170 175  
 Ile Glu Val Ser Arg Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala  
 180 185 190  
 Leu Leu Lys Leu Ser Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro  
 195 200 205  
 Ala Cys Leu Pro Ser Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys  
 210 215 220  
 Phe Ile Thr Gly Trp Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu  
 225 230 235 240  
 Leu Lys Glu Ala Gln Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg  
 245 250 255  
 Tyr Glu Phe Leu Asn Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly  
 260 265 270  
 His Leu Ala Gly Gly Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro  
 275 280 285  
 Leu Val Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser  
 290 295 300  
 Trp Gly Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg  
 305 310 315 320  
 Val Ser Arg Phe Val Thr Trp Ile Glu Gly Val Met Arg Asn Asn  
 325 330 335

<210> 3

<211> 2432

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (0)...(0)

<223> Human plasminogen

<400> 3

atggAACATA aggaAGTGGT tcttctactt ctTTTATTTC tGAAATCAGG tcaAGGAGAG 60  
 CCTCTGGATG actatgtgaa tacccAGGGG gcttcaCTGT tcAGTGTcAC taAGAAGCAG 120  
 ctggGAGCAG gaAGTATAGA agaatgtcA gcaAAATGTG aggAGGACGA agaATTcacc 180

tgcaggggcat	tccaaatata	cagttaaagag	caacaatgtg	tgataatggc	tggaaaacagg	240
aaggctccca	taatcattag	gatgagagat	gtatgtttat	ttgaaaagaa	agtgtatctc	300
tcagagtgc	agactggaa	tggaaagaac	tacagaggga	cgtatgtccaa	aacaaaaat	360
ggcatcacct	gtcaaaaatg	gagttccact	tctccccaca	gacctagatt	ctcacctgct	420
acacacccct	cagagggact	ggaggagaac	tactgcagga	atccagacaa	cgatccgcag	480
gggcctgtgt	gctatactac	tgatccagaa	aagagatatg	actactgcga	cattcttgag	540
tgtgaagagg	aatgtatgc	ttgcagttga	gaaaactatg	acggcaaat	ttccaagacc	600
atgtctggac	tggaatgcca	ggcctgggac	tctcagagcc	cacacgctca	tggatacatt	660
ccttccaaat	ttccaaacaa	gaacctgaag	aagaattact	gtcgttaacc	cgatagggag	720
ctggcgcctt	gggtttcac	caccgacccc	aacaaggcgt	gggaactttg	cgacatcccc	780
cgctgcacaa	cacctccacc	atcttctgtt	cccacatcc	agtgtctgaa	gggaacaggt	840
gaaaactatc	gcggaaatgt	ggctgttacc	gtttccgggc	acacctgtc	gcactggagt	900
gcacagaccc	ctcacacaca	taacaggaca	ccagaaaact	tcccctgcaa	aaatttggat	960
gaaaactact	gcccgaatcc	tgacggaaaa	agggccccat	ggtgccat	aaccaacagc	1020
caagtgcgtt	gggagttactg	taagataccg	tcctgtgact	cctccccagt	atccacggaa	1080
caattggctc	ccacagcacc	acctgagcta	accctgtgg	tccaggactg	ctaccatggt	1140
gatggacaga	gctaccgagg	cacatcctcc	accacccacca	cagggaaagaa	gtgtcagtct	1200
tgttcatctt	tgacaccaca	ccggcaccag	aagaccccg	aaaactaccc	aatgtctggc	1260
ctgacaatga	actactgcag	gaatccagat	ggcgataaaag	gcccctgg	ttttaccaca	1320
gaccggcgcg	tcaggtggga	gtactgcaac	ctgaaaaaat	gctcaggaa	agaagcga	1380
gtttagcac	ctccgcctgt	tgtctctgtt	ccagatgtag	agactcctc	cgaagaagac	1440
tgtatgttt	ggaatggaa	aggataccga	ggcaagagg	cgaccactgt	tactgggacg	1500
ccatgccagg	actgggctgc	ccaggagccc	catagacaca	gcattttcac	tccagagaca	1560
aatccacggg	cgggtctgga	aaaaaaattac	tgccgttaacc	ctgatggtg	tgttagttgt	1620
ccctgggtct	acacgacaaa	tccaaagaaaa	ctttacgact	actgtgtatg	ccctctgt	1680
gccccccctt	catttatttg	tgggaaagcc	caagtggagc	cgaagaaaatg	tccttggagg	1740
gttgtgggg	ggtgtgtggc	ccacccacat	tcctggccct	ggcaagtca	tctttagaaaca	1800
aggtttggaa	tgcacttctg	tggaggcacc	ttgatatccc	cagagtgggt	gttactgt	1860
gcccactgt	tggagaagtc	cccaaggcct	tcatcttaca	aggtcatct	gggtgcacac	1920
caagaagtga	atctcgaaacc	gcatgttca	gaaatagaag	tgtcttaggt	gttcttggag	1980
cccacacaa	aagatata	cttgctaaag	ctaagcagtc	ctgcccgtat	cactgacaaa	2040
gtaatcccg	cttgcgtgc	atccccaaat	tatgtgtcg	ctgaccggac	cgaatgtttc	2100
atcaactggc	ggggagaaac	ccaagggtact	tttgaggtcg	gccttctca	ggaagccccag	2160
ctccctgtga	tttggataata	agtgtcaat	cgctatgagt	ttctgtatgg	aagagtccaa	2220
tccaccgaac	tctgtgtgg	gcatttggcc	ggaggcactg	acagttgc	gggtgacagt	2280
ggaggtcctc	tggtttgctt	cgagaaggac	aaatacattt	tacaaggagt	cacttcttgg	2340
ggcttggct	gtgcacgccc	caataagcc	ggtgtctatg	ttcgtgtttc	aaggtttgtt	2400
acttggattt	agggagtgtat	gagaataat	ta			2432

<210> 4  
<211> 810  
<212> PRT  
<213> *Homo sapiens*

<220>  
<221> PEPTIDE  
<222> (0)...(0)  
<223> Human plasminogen

```

<400> 4
Met Glu His Lys Glu Val Val Leu Leu Leu Leu Phe Leu Lys Ser
      1           5           10          15
Gly Gln Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser
      20          25          30
Leu Phe Ser Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu
      35          40          45
Cys Ala Ala Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe
      50          55          60
Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg

```

65	70	75	80												
Lys	Ser	Ser	Ile	Ile	Arg	Met	Arg	Asp	Val	Val	Leu	Phe	Glu	Lys	
85									90					95	
Lys	Val	Tyr	Leu	Ser	Glu	Cys	Lys	Thr	Gly	Asn	Gly	Lys	Asn	Tyr	Arg
100								105						110	
Gly	Thr	Met	Ser	Lys	Thr	Lys	Asn	Gly	Ile	Thr	Cys	Gln	Lys	Trp	Ser
115								120				125			
Ser	Thr	Ser	Pro	His	Arg	Pro	Arg	Phe	Ser	Pro	Ala	Thr	His	Pro	Ser
130						135				140					
Glu	Gly	Leu	Glu	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro	Gln
145					150				155					160	
Gly	Pro	Trp	Cys	Tyr	Thr	Thr	Asp	Pro	Glu	Lys	Arg	Tyr	Asp	Tyr	Cys
165							170					175			
Asp	Ile	Leu	Glu	Cys	Glu	Glu	Cys	Met	His	Cys	Ser	Gly	Glu	Asn	
180							185					190			
Tyr	Asp	Gly	Lys	Ile	Ser	Lys	Thr	Met	Ser	Gly	Leu	Glu	Cys	Gln	Ala
195							200					205			
Trp	Asp	Ser	Gln	Ser	Pro	His	Ala	His	Gly	Tyr	Ile	Pro	Ser	Lys	Phe
210						215					220				
Pro	Asn	Lys	Asn	Leu	Lys	Lys	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Arg	Glu
225					230				235					240	
Leu	Arg	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro	Asn	Lys	Arg	Trp	Glu	Leu
245								250					255		
Cys	Asp	Ile	Pro	Arg	Cys	Thr	Thr	Pro	Pro	Pro	Ser	Ser	Gly	Pro	Thr
260								265					270		
Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Glu	Asn	Tyr	Arg	Gly	Asn	Val	Ala
275							280					285			
Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr	Pro
290							295					300			
His	Thr	His	Asn	Arg	Thr	Pro	Glu	Asn	Phe	Pro	Cys	Lys	Asn	Leu	Asp
305							310				315				320
Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys	His
325								330					335		
Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Glu	Tyr	Cys	Lys	Ile	Pro	Ser	Cys
340							345					350			
Asp	Ser	Ser	Pro	Val	Ser	Thr	Glu	Gln	Leu	Ala	Pro	Thr	Ala	Pro	Pro
355							360					365			
Glu	Leu	Thr	Pro	Val	Val	Gln	Asp	Cys	Tyr	His	Gly	Asp	Gly	Gln	Ser
370						375					380				
Tyr	Arg	Gly	Thr	Ser	Ser	Thr	Thr	Thr	Gly	Lys	Cys	Gln	Ser		
385							390			395				400	
Trp	Ser	Ser	Met	Thr	Pro	His	Arg	His	Gln	Lys	Thr	Pro	Glu	Asn	Tyr
405								410					415		
Pro	Asn	Ala	Gly	Leu	Thr	Met	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Asp
420							425					430			
Lys	Gly	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro	Ser	Val	Arg	Trp	Glu	Tyr
435							440					445			
Cys	Asn	Leu	Lys	Lys	Cys	Ser	Gly	Thr	Glu	Ala	Ser	Val	Val	Ala	Pro
450							455					460			
Pro	Pro	Val	Val	Leu	Leu	Pro	Asp	Val	Glu	Thr	Pro	Ser	Glu	Glu	Asp
465							470			475				480	
Cys	Met	Phe	Gly	Asn	Gly	Lys	Gly	Tyr	Arg	Gly	Lys	Arg	Ala	Thr	Thr
485								490					495		
Val	Thr	Gly	Thr	Pro	Cys	Gln	Asp	Trp	Ala	Ala	Gln	Glu	Pro	His	Arg
500							505					510			
His	Ser	Ile	Phe	Thr	Pro	Glu	Thr	Asn	Pro	Arg	Ala	Gly	Leu	Glu	Lys
515							520					525			
Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Asp	Val	Gly	Gly	Pro	Trp	Cys	Tyr
530							535					540			

Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys  
 545 550 555 560  
 Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys  
 565 570 575  
 Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala His Pro His Ser Trp  
 580 585 590  
 Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly  
 595 600 605  
 Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu  
 610 615 620  
 Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His  
 625 630 635 640  
 Gln Glu Val Asn Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg  
 645 650 655  
 Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser  
 660 665 670  
 Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser  
 675 680 685  
 Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp  
 690 695 700  
 Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln  
 705 710 715 720  
 Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn  
 725 730 735  
 Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly  
 740 745 750  
 Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu  
 755 760 765  
 Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys  
 770 775 780  
 Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val  
 785 790 795 800  
 Thr Trp Ile Glu Gly Val Met Arg Asn Asn  
 805 810

&lt;210&gt; 5

&lt;211&gt; 79

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; kringle domain 1 of native human plasmin(ogen)

&lt;400&gt; 5

Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr  
 1 5 10 15  
 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg  
 20 25 30  
 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn  
 35 40 45  
 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr  
 50 55 60  
 Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys  
 65 70 75

&lt;210&gt; 6

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; kringle domain 2 of native human plasmin(ogen)

&lt;400&gt; 6

Cys	Met	His	Cys	Ser	Gly	Glu	Asn	Tyr	Asp	Gly	Lys	Ile	Ser	Lys	Thr
1					5					10					15
Met	Ser	Gly	Leu	Glu	Cys	Gln	Ala	Trp	Asp	Ser	Gln	Ser	Pro	His	Ala
						20				25					30
His	Gly	Tyr	Ile	Pro	Ser	Lys	Phe	Pro	Asn	Lys	Asn	Leu	Lys	Lys	Asn
						35			40					45	
Tyr	Cys	Arg	Asn	Pro	Asp	Arg	Glu	Leu	Arg	Pro	Trp	Cys	Phe	Thr	Thr
						50			55			60			
Asp	Pro	Asn	Lys	Arg	Trp	Glu	Leu	Cys	Asp	Ile	Pro	Arg	Cys		
						65			70			75			

&lt;210&gt; 7

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; kringle domain 3 of native human plasmin(ogen)

&lt;400&gt; 7

Cys	Leu	Lys	Gly	Thr	Gly	Glu	Asn	Tyr	Arg	Gly	Asn	Val	Ala	Val	Thr
1					5				10						15
Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr	Pro	His	Thr
						20			25				30		
His	Asn	Arg	Thr	Pro	Glu	Asn	Phe	Pro	Cys	Lys	Asn	Leu	Asp	Glu	Asn
						35			40				45		
Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys	His	Thr	Thr
						50			55			60			
Asn	Ser	Gln	Val	Arg	Trp	Glu	Tyr	Cys	Lys	Ile	Pro	Ser	Cys		
						65			70			75			

&lt;210&gt; 8

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; kringle domain 4 of native human plasmin(ogen)

&lt;400&gt; 8

Cys	Tyr	His	Gly	Asp	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Ser	Ser	Thr	Thr
1						5				10					15
Thr	Thr	Gly	Lys	Lys	Cys	Gln	Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Arg
						20			25			30			
His	Gln	Lys	Thr	Pro	Glu	Asn	Tyr	Pro	Asn	Ala	Gly	Leu	Thr	Met	Asn
						35			40			45			
Tyr	Cys	Arg	Asn	Pro	Asp	Ala	Asp	Lys	Gly	Pro	Trp	Cys	Phe	Thr	Thr
						50			55			60			
Asp	Pro	Ser	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Lys	Lys	Cys		
						65			70			75			

<210> 9  
<211> 80  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> kringle domain 5 of native human plasminogen

<400> 9  
Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr  
1 5 10 15  
Val Thr Gly Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg  
20 25 30  
His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys  
35 40 45  
Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr  
50 55 60  
Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys  
65 70 75 80